CN101124335A - High throughput proteomics - Google Patents

Abstract

Methods to obtain expression systems and proteins in a high-throughput protocol by utilizing mixtures of cells cultured from those transformed with a desired nucleotide sequence permit rapide production of protein for use in arrays to assess activity. In one embodiment, the proteins (or peptides) in the array are assessed for their immunological activity with regard to an infectious agent.

Description

High throughput proteomics

The mutual reference of related application

[0001] the application requires the rights and interests of U.S. Provisional Application of submitting on July 1st, 2,004 60/585,351 and the U.S. Provisional Application of submitting on December 23rd, 2,004 60/638,624.The content that is incorporated herein these applications as a reference.

Rights statement to the invention carried out under the research of federal funding

[0002] this working portion has obtained health ministry/national transformation reactions and has infected the sick support of learning.United States Government enjoys some right to the present invention.

Technical field

[0003] the present invention relates to prepare the method for albumen or peptide from coding property open reading-frame (ORF) (ORF), and the method for evaluation immunoreactive protein.The present invention also relates to prepare the method for albumen/peptide array from a plurality of coding ORF, and the purposes of these arrays in measuring immunoreactive protein.The present invention also relates to these immune-active peptides and use their method.

Background technology

[0004] knownly for a long time contain recombinase system such as intestinal bacteria and zymic microorganism, it realizes homologous recombination not needing to provide under the condition of exogenous enzyme such as ligase enzyme.For example, Oliner, J.D., et al, Nucleic Acids Res. (1993) 21:5192-5197 has described the method for clone PCR products, and this method is by the identical end sequence of sequence with linearizing carrier two ends is provided to them.Product and carrier DNA cotransfection in coli strain JC8679, are carried out recombinating in the body to carrier and PCR product.By identifying the bacterium colony that contains recombinant plasmid with the hybridization of diagnostic DNA.The author has proposed the prioritization scheme with this method clone gene group PCR product in intestinal bacteria.

[0005] nearest, Zhang, Y., et al, Nature Genetics (1998) 20:123-128 has described similar methods, thinks that this method has increased the size of the DNA that can pass through this method clone.

[0006] U.S. applies for that openly 2003/0044820 has described with PCR nucleic acid fragment is cloned into method in the carrier, and this method has adopted the linking sequence, and described sequence can contain functional element, as promotor, terminator, selective marker etc.By the linearizing carrier of pcr amplification, rather than prepare linearizing carrier by routine clone and digestion subsequently.This has increased provides the advantage of additional sequences for linearizing carrier, and described sequence can be mated the connection portion of the nucleic acid of pcr amplification.The unique system that is used to select have the bacterium colony of recombinant plasmid has also been described.

[0007] nearest, Parrish, J., et at, J.Proteome Res. (2004) 3:582-586 have described the parameter that influences the cloning efficiency that adopts the routine techniques of recombinating in intestinal bacteria.In this work, the frame that has increased and in campylobacter jejuni, identified, and the linearized vector in the insertion intestinal bacteria.Separate each bacterium colony, the clone is checked order.Adopted the amplification right to the primer of the total length ORF of 1,685 kind of gene of genome sequence prediction, wherein determined should biology described genome sequence.1,346 kind of PCR product is visible on gel, and 75% in these genes provide to have and contain the bacterium colony that inserts segmental carrier.

[0008] also known cell except that intestinal bacteria with recombinase function.For example, Ma, H., Kunes, S., Schatz, PJ.and Botstein, D., Gene (1987) 58:201-216 has shown that Saccharomyces cerevisiae can carry out this reorganization.

[0009] aforementioned every kind of method all needs to separate the mono-clonal that is used to produce every kind of target protein, and this is the step that is difficult to be suitable for high throughput processes, and may cause the separation of mutant rather than intact proteins.Therefore, preceding method all can not easily provide great majority or a large amount of albumen of all complete genome groups, the i.e. Sheng Wu intact proteins group of for example representing infectious agent (infectious agent) in a large number.Therefore, still need to make it possible to prepare the high-throughput scheme of described protein groups array, can analyze this array, obtain various interactions and characteristic.

[0010] one of purposes of described array is to identify the immunoreactive protein that produces by by infectious biological, as a step of anti-this biological vaccine of exploitation.A lot of forms have been adopted in the effort of the described antigenic protein in the evaluation infectious agent.In hydropathic profile, analyze albumen, for example, determined and to expose, therefore can contact immune zone.Perhaps, (as United States Patent (USP) 6,620, the description in 412 and 6,451,309) detected in 400 kinds of monoclonal antibodies and the ability of virus, detected the ability that their protection mouse avoid attacking then.Thus the antibody of Jian Dinging associate in they immunoreactive albumen.Many such albumen have been identified.

[0011] U. S. application 2003/0082579 has been described by the protein arrays that derives from infectious biological with at least a antibody screening that exists in the immune serum and has been identified antigenic method, and described immune serum carries out stimulation oversaturation with this biology or biological part.By pcr amplification coding property DNA, carry out second then and take turns pcr amplification to import transcriptional control sequence; Take turns the external albumen that is translated as of product with second then, obtained the albumen in the array.But clearly, if attempt in the high-throughput mode, the method for the acquisition protein arrays of description has produced albumen in shortage.

[0012] therefore, these methods have proved passes through to screen albumen or the proteic part of the albumen of infectious agent with the evaluation induce immune response, can find useful antigenic protein in vaccine and diagnosis are developed.But because they need be at every kind of albumen sepn mono-clonal, they can not be provided for identifying the antigenic high throughput method of characteristic of infectious agent, and described characteristic antigen has been represented the possible antigenic protein or the four corner of peptide moiety.Need described fast method to come rapid answer, with vaccine or the diagnostic test of exploitation at new infectious agent biological example weapon.By allowing synthetic albumen/peptide array of representing the intact proteins group substantially, and, the invention provides the chance of most possible material standed for that rapid evaluation is used for the stimulant of diagnostic test, vaccine and T cellular immunization by providing the means that realize it with practical ways that can automatization.

Summary of the invention

[0013] on the one hand, the present invention relates to identify the method for albumen or peptide with immunogen activity based on to deriving from investigation such as the repertoire of the major portion of the genomic albumen of the infectious agent of virus, protozoon, parasite or bacterium or peptide or complete substantially expression.This method allow to show in the genome of the described infectious agent of representative 48-albumen and/or the peptide of all open reading-frame (ORF)s substantially, and allow to use from every kind of albumen in the immune serum of the individuality that is exposed to described infectious agent or the blood plasma hot-wire array and/or peptide.Therefore, this method finally makes it possible to identify the basic all immune-active peptides by the genome encoding of infectious agent.

[0014] in general, the present invention has many aspects, relates to preparing immune-active peptides or the proteic peptide/protein arrays that is used to identify from infectious agent, also relates in general to preparation albumen/peptide array.These methods allow preparation to contain the peptide or the proteic array of the genomic signal portion of representing infectious agent.These arrays can be used to identify can inducing cell and/or the immune-active agent of humoral immunoresponse(HI).The present invention also relates to the specific antigens of so evaluation and have immunoreactive monoclonal antibody with them.These antigens, their nucleic acid and antibody may be used to prepare the immunogenic composition of the diagnosis, prevention and the therapeutic treatment that are used at infectious agent.Therefore, on the one hand, the present invention relates to obtain the method for the expression system of the nucleotide sequence that needs, described method does not adopt the selection of each colony, but makes the user obtain these expression systems from the results of cell, the mixture of cultivation.The ratio that the nucleic acid that extracts and being used to obtains transformant also is an aspect of of the present present invention.

[0015] another aspect of the present invention relates to by method preparation of the present invention, or represents the peptide/protein arrays of the genomic signal portion of infectious biological.The present invention also relates to the antigen of evaluation as indicated above and use these antigenic methods, their corresponding monoclonal antibody and their nucleic acid molecule of encoding.Can be directly used in the serology test, with the antigen of antibody response in sufferer's serum with the diagnose infections patient.

[0016] on the one hand, the present invention relates to obtain the method for the expression system of the nucleotide sequence that needs.This method can be used the expression system transformed host cells with the nucleotide sequence that needs, or with the recombinase-competence host cell that can dress up the composition conversion of expression system by described groups of cells.Described expression system is plasmid typically; Host cell can be chemoreception attitude bacterium, yeast or electroporation competence bacterium; In certain embodiments, host cell is a yeast, as Saccharomyces cerevisiae or bacterium, as intestinal bacteria, and can comprise at least a coli strain that is selected from JC8679, TB1, DH5 α, DH5, HB101, JM101, JM109 and LE392.

[0017] composition of expression system can comprise linearizing plasmid, from least one open reading-frame (ORF) of biology interested, or the part of described ORF and being designed for guarantees that plasmid that ORF can linearization of montage is to generate one or more adapters of novel plasmid.Therefore, each described adapter contain with an end complementary first nucleotide sequence of linearizing plasmid and with an end complementary second nucleotide sequence of genome ORF.Two such adapters of appropriate designs can be used for ORF is inserted linearizing plasmid, produce novel plasmid, and it has the nucleotide sequence of the suitable ORF that meets the open reading-frame (ORF) of plasmid and insert.

[0018] adapter can be chosen the feature that further comprises the one or more interpolations of coding that meet ORF such as the nucleotide sequence of epi-position mark wantonly, makes that expressed proteins will be the fusion rotein that comprises the peptide of the ORF coding that is connected with the epi-position mark.Described epi-position mark can be used for peptide or proteic detection, purifying or the location of being expressed.The epi-position mark that is used for this purpose can include, but are not limited to one or more following marks: 3-12 the successive histidine residues of encoding, the polyhistidine tag of 6-10 described residue usually; Hemagglutinin (HA) mark; The c-Myc mark; The Biotin-ligase recognition site; Gsh-S-adenylyl transferase (GST) mark; Fluorescin is as GFP; The FLAG-mark; And joint.Because use two such adapters usually, these elements can be included on one or two described adapter; For example, on an adapter, comprise polyhistidine tag, on another adapter, comprise the HA mark, make and utilize two kinds of different detections or localization method for single expressing protein.In some embodiments of the present invention, on arbitrary adapter or linearizing plasmid, comprise one or more other functional element; The placement of described element and selection are well known in the art.Described element can comprise promotor, terminator sequence, operon, fusion mark, signal peptide or other functional peptides, antisense sequences and ribozyme.

[0019] nucleotide sequence that will express can comprise the sequence from the biological gene group, in some embodiments, it is selected, to comprise the open reading-frame (ORF) (ORF) from the gene of interested biology.In some embodiments, described biology is a microorganism, and in some embodiments, it is an infectious agent.Nucleotide sequence comprise biological as the genomic embodiment of the part of infectious agent in, the adapter of method employing of the present invention comprises one or more epi-position marks; The representative example of described mark comprises HA, c-Myc and has the polyhistidyl of at least 6 continuous histidine residues.

[0020] in one aspect of the invention, before use by fixed genome nucleotide sequence and the linearizing plasmid of the interested target of pcr amplification, each 1,000,000 cell adopts fixed nucleotide sequence and the linearizing plasmid of 1-10ng target; In others, the nucleotide sequence that target is fixed and the amount of linearizing plasmid can be bigger.In some embodiments, the mol ratio of nucleotide sequence and plasmid can be about 1: 1; In other embodiments, it is 1: 10-10: 1; In other embodiments, it is 100: 1-1: 100.

[0021] culturing cell in the presence of these compositions then, and results extract expression system from the mixture of transformant.In another aspect of this invention, need before separating expression system, not separate mono-clonal.On the contrary, cultured cells is with " mixture " results, and directly from the cellular segregation expression system of results, the typical case is a plasmid.Therefore, this method is favourable for the mode of the described expression system of preparation of high-throughput and automatization, and more successful in the plasmid of albumen that reclaims the coding needs or peptide.Back one advantage has reflected that method of the present invention has prevented to select inaptly sudden change or contained the colony of unwanted plasmid (rather than plasmid of seeking) and the loss of the needs ground expression system that causes.

[0022] expression system that so produces can be used for deriving from system's one or more peptides of preparation or the albumen of cell, and described system can the accurate translation system, with the peptide of preparation coding.The system that derives from cell can be in intact cell, or it can be the necessary enzyme and the acellular mixture of composition.In some embodiments, the system that derives from cell is a bacterium, as intestinal bacteria (E.coli); Or yeast; Or prokaryotic cell prokaryocyte.In other embodiments, it is the eukaryotic cell such as mammalian cell, as reticulocyte, perhaps can be insect cell.In certain embodiments, expression system is imported antigen presenting cell (APC), as dendritic cell, B cell or scavenger cell.In other embodiments, the translation of employing/transcribe cell is a cell free system, and it can derive from such as colibacillary microorganism, or derives from the eukaryotic cell such as reticulocyte, or derives from the vegetable cell such as wheat germ.

[0023] in one embodiment, albumen or peptide are represented one or more genes of host genome.Therefore, method of the present invention can be used to prepare the gene of described genomic any subgroup of encoding, and can be used to prepare the described genomic great majority of coding or one group of plasmid of all genes or the array of plasmid substantially.In certain embodiments, genome is the genome of infectious agent.

[0024] expression system by method acquisition of the present invention and expression can be used to prepare the genomic albumen of described representative infectious agent or other biology or the array of peptide.These arrays can be used for others of the present invention, and it relates to the antigen that evaluation will be induced body fluid and/or cellullar immunologic response.This method comprises with at least a albumen or the peptide of method herein preparation or represent the albumen of basic all albumen/peptides of the open reading-frame (ORF) coding in the genome of infectious agent and/or the array of peptide is exposed to the experimenter's who is exposed to infectious agent immune serum or blood plasma that this experimenter can be called " immune experimenter ".Exposure can be the part inoculation of for example passing through with the attenuation form or the infectious agent of infectious agent, or is infected by described infectious agent.What comprise in the array demonstrates the possible material standed for that is accredited as production of vaccine with the immunoreactive albumen/peptide of described serum, blood plasma or composition.If array comprises full-length proteins, this method can further comprise the step that the additional arrays that derives from the antigenic peptide of being identified by preceding method is provided, wherein said peptide is represented the fragment of antigenic peptide, and makes it possible to be positioned on the peptide antigenic epitopes is more accurate.Perhaps, can analyze full-length proteins or longer peptide, may show maximum immunocompetent zone to identify with method well known in the art such as hydropathic profile.Be accredited as immunoreactivity and may be used for the same protein of vaccine preparation or peptide also can be directly used in the serodiagnosis test, to identify the infectious agent of being responsible for infected disease of patient.The patient who does not have the serum antibody of anti-given infectious agent encoded protein is not subjected to the infection of this infectious agent.Patient with anti-proteic antibody from infectious agent has been infection recently, or certain time has been infection in the past.

[0025] be used to identify that immune-active peptides or proteic peptide/protein arrays can represent the genomic signal portion of infectious agent, as 50%, or they can represent great majority (＞50%) or basic all (at least 98%) amino acid sequence coded.In some embodiments, prepare proteic array by method of the present invention.In some embodiments, the albumen of method of the present invention preparation or peptide or array are exposed to immunizing composition from the experimenter of a plurality of immunity, be accredited as immunodominance antigen from the albumen or the peptide of experimenter's induce immune response of most of at least immunity, and be included in the suitable candidate in the vaccine.In some embodiments, also with array or albumen this area serum from non-immune experimenter, will be in the experimenter of immunity induce immune response, but in non-immune experimenter not the albumen of induce immune response be chosen as and be applicable to vaccine.

[0026] in some embodiments of the present invention, detect humoral immunoresponse(HI) by at least a antibody that detects from the experimenter of immunity with combining of albumen or peptide.Can observe combining of albumen and antibody by means commonly known in the art, comprise that needs adopt the method for second antibody, described second antibody is carried out mark with for example fluorescent marker, radioactively labelled substance or enzyme.

[0027] in some embodiments of the present invention, can detect cellullar immunologic response.The related immune composition is the T cell from the experimenter of immunity.In described embodiment, observe and when described one or more peptides of T cells contacting or albumen, form at least a cytokine, thereby detect immunne response by the T cell.For described embodiment, can present peptide or albumen by antigen presenting cell (APC), in some embodiments, APC is used for from the plasmid expression peptide or the albumen of method acquisition of the present invention.In other embodiments, albumen or peptide are expressed as the fusion rotein that contains at least a epi-position mark, and described epi-position mark is used for albumen or peptide are fixed in the surface.In some embodiments, the surface is less than the particle of APC or pearl, therefore can be by the APC picked-up such as scavenger cell; In a kind of described embodiment, particle be nickel bead or bag by the pearl of nickel or nickel salt or complex compound, and peptide or albumen comprise the polyhistidyl epi-position mark with at least 6 continuous histidine residues.Can peptide be fixed on the nickeliferous pearl by the avidity of polyhistidine tag then nickel.

[0028] on the other hand, the invention provides detection available from experimenter's immunizing composition method to the immunne response of test substances, described test substances is included in the sample that contains other antigenicity substance, and the experimenter may show immunne response to described other antigenicity substance.These situations may come from, and for example, when expressing in the albumen experimenter that will test is deriving from the system of cell, and the experimenter may once be exposed to described system, so the experimenter shows immunne response to it.In the method, at first handle immunizing composition, thereby before handling immunizing composition, block any immune response uncorrelated antigenicity substance with described test substances available from the experimenter with extra, incoherent antigenicity substance.For example, if in deriving from colibacillary system, produce albumen or the peptide that to test, can derive from human experimenter's immunizing composition sample with the intestinal bacteria extract-treated, to block the background immunne response that the mankind may show multiple bacillus coli antigen.Then, can be in advance with colibacillary lysate or extract-treated sample from the experimenter.

[0029] in general, the present invention relates to provide by open reading-frame (ORF) (ORF) or each albumen of its part coding or the method for peptide, this method is included in encoding said proteins or peptide are expressed in extraction in the expression system (as plasmid) of the mixture (not being the clone) of recombinase competent cell insertion fragment, described cell is modified, to comprise described insertion fragment and linearizing plasmid; Wherein said linearizing plasmid with insert fragment and be connected by homologous recombination in the body in the described cell, and wherein from described ORF or its part described insertion fragment that increased.In a kind of particular, self has obtained amplification linearization plasmid.Can increase by PCR.For example, can be at cell free system or provide in the cell of the posttranslational modification that needs and express, to produce albumen.This method can allow to produce simultaneously multiple protein or peptide.In some embodiments, can produce 10,50,100,200,400,600,800,1000,1500,2000 or different albumen or peptide more than 2000 kind simultaneously.

[0030] the invention provides production by the great majority of infectious agent or biological genome encoding or the method for all albumen or peptide substantially.Thus obtained albumen or peptide may be included in respectively or can point sample in matrix, on nitrocellulose or plate or chip, so that on test surfaces, produce the array of albumen or peptide.In some embodiments, each described albumen or peptide can merge with one or more epi-position marks, this make it possible to the albumen after the translation detect, location or purifying.The epi-position mark can be used for albumen or peptide are fixed on the surface of carrying complementary binding substance or being made up of described material, and described material for example is the nickel surface that can combine closely with the polyhistidine tag of expressed proteins.Therefore, in some embodiments, the interested peptide of expression and epi-position mark merge, and described epi-position mark is used for being fixed on peptide such as pearl or measuring the surface of plate hole.In one embodiment, the epi-position mark is the polyhistidyl sequence that contains at least 6 continuous histidine residues, has fixed one or more described proteic surfaces and has comprised nickel.

[0031] in another embodiment, the present invention relates to obtain to comprise the method for inserting segmental plasmid, described insertion fragment comprises the nucleotide sequence as ORF or its part, this method comprises from the mixture of recombinase competence microorganism (not being the clone) extracts described plasmid, described microorganism is modified, containing linearizing carrier and comprise the nucleic acid of the amplification of described ORF or its part, and realize the reorganization of described insertion fragment and described linearizing plasmid by homologous recombination.

[0032] on the other hand, the present invention relates to identify and to produce the antigenic method of humoral immunoresponse(HI) to infectious agent, this method comprises that the immunoglobulin (Ig) that makes the albumen that obtains by method of the present invention and/or peptide and immune serum or blood plasma or wherein comprise contacts, described immune serum, each material in blood plasma and the immunoglobulin (Ig) is all available from being exposed to optional the be in infectious agent of attenuation form or the experimenter of its some parts, the contact mode estimate induce immune response, and will with blood plasma, immunoreactive those albumen of serum or isolating immunoglobulin (Ig) or peptide are accredited as suitable antigen.In some embodiments, described peptide/albumen has been represented the most of of described infectious agent or basic full gene group, and immunoreactivity has comprised combining of at least a antibody that reacts on infectious agent with the experimenter and produce.Can adopt reorganization acquisition plasmid in the body according to above-described method, express in deriving from the system of cell then, to obtain albumen or peptide, described system can perhaps can be a cell free system in intact cell.In some cases, may need to handle serum or blood plasma, so that background immune response minimum with the lysate of the biology that has carried the system that derives from cell that is used for expressing protein.In some embodiments, obtain to derive from the system of cell, block background immunne response the composition of the system that derives from cell with colibacillary extract or lysate from intestinal bacteria.In some embodiments, can detect combining of albumen or peptide and antibody,, second antibody carried out mark with fluorescence, radioactivity or enzyme labelling group for the ease of detecting with second antibody.

[0033], the present invention relates to identify the antigenic method that infectious agent is produced cellullar immunologic response in others.This method can be similar to method mentioned above, but can use experimenter's dendritic cell or immune other cellular constituent as immunocompetent diagnostic reagent.In certain embodiments, by for example making albumen can be fixed on the polyhistidyl epi-position mark on the pearl of nickel bag quilt mixing on the expressed proteins, albumen that method mentioned above is provided or peptide are fixed on the matrix such as pearl, then fixed albumen or peptide are exposed to APC.Advantageously, matrix is the structure such as pearl, and it is less than APC, therefore by described APC internalization.Then described APC is exposed to the responsive cell of at least a type, as carried out the experimenter's of anti-infection agent immunity T cell by method mentioned above, described responsive cell or T cell produce one or more cytokines, have proved to exist this proteic immunne response.Therefore, in this embodiment, by detecting the formation when T cellular exposure one or more cytokines during in APC, can detect immunne response, described APC had been exposed to peptide or albumen.Perhaps, the propagation of the cellular cytoxicity activity of described responsive cell of observation or T cell can be passed through, immunne response can be detected.

[0034] in a single day identified antigenic protein, just can be with method screening albumen of the present invention, to identify the immunogenicity zone on the albumen more accurately.This is by providing the fragment that is designed for expressing protein to finish, and the length in described zone can be for example 10-20 or 20-30 or 20-50 or 20-100 amino acid, but also can adopt shorter or longer fragment suitable the time.Express and analyze these shorter fragments by method of the present invention then, identify the peptide that produces the antigenicity effect thus.Randomly, these fragments can be designed as eclipsed, make to miss antigenic chance minimum, because it strides two fragments.

[0035] in others, the present invention relates to array by the albumen/peptide of method acquisition of the present invention, relate to the antigen of identifying from described array, relate to the immunodominance antigen of identifying by method of the present invention, relate to and comprise at least a described antigenic vaccine composition, and the dna vaccination composition that comprises at least a described antigenic nucleotide sequence of encoding, and relate to and contain at least a antigenic serum blood diagnostic test of identifying by aforesaid method.In others, it relates at least a described antigenic specific antibody, particularly monoclonal antibody, and relates to the composition that comprises described antibody.Relate on the other hand and use composition of the present invention, comprise antigen, antigen, vaccine and dna vaccination immunity experimenter's method and for example utilize treatment to go up or diagnose that going up nucleic acid and/or the antigen identified with these methods determines clearly whether individuality infects or infected in the past particular organisms.

[0036] in certain embodiments of the invention, each gene in one group of gene of biological gene group be will be selected from the method for production expression system described herein and biological self plasmid, the optional epi-position mark that comprises of described plasmid mixed; And produce described proteic array, it represents great majority or all substantially albumen (intact proteins group) of described biology.This biology can be an infectious agent, draw hot Frances Salmonella (tularemia) or viral hemorrhagic fever virus as Bacillus anthracis (anthrax), Clostridium botulinum, Yersinia pestis, smallpox and other poxvirus, soil, comprise arenavirus (as LCM, Junin virus, Machupo virus, Guanarito virus, Lassa fever virus), cloth Buddhist nun virus (as Hantaan virus, valley fever virus), flavivirus (as dengue fever virus) or filovirus (as Ebola virus, Marburg virus).Biology also can be an infectious agent, as the pseudoglanders bulkholderia cepasea, Bai Shi cock steadite (Q heat), brucella kind (brucellosis), glanders bulkholderia cepasea (glanders), Ricin (from castor-oil plant), the ε toxin of clostridium perfringens, staphylococcal enterotoxin B, typhus fever (Rickettsia prowazekii) or food and water-borne pathogenic agent comprise that bacterium (as causes the diarrhoea intestinal bacteria, morbid vibrio, the Shigellae kind, salmonella, Listeria monocytogenes, campylobacter jejuni, yersinia entero-colitica), virus (Calicivirus, hepatitis A virus) or protozoon (as Cryptosporidium parvum, Cyclospora cayatanensis, table is suck giardia lamblia, toxoplasma, little spore belongs to).Described biology also can be such as viral encephalitis virus, comprises the infectious agent of west Nile virus, LaCrosse virus, california antigenic group viruses, VEE, EEE, WEE, japanese encephalitis virus or Ke's Sanur forest virus.Described biology also can be the infectious agent of levying relevant coronavirus (SARS-CoV) such as Nipah virus, Hantaan virus, tick-borne hemorrhagic fever virus (as crimean-Congo hemorrhagic fever virus), tick-borne encephalitis, yellow fever virus, multi-drug resistance TB virus, influenza virus, Rickettsiae, rabies or serious acute respiratory system synthesis.In some embodiments, it is that soil draws hot Frances Salmonella, human papillomavirus, west Nile virus, pseudoglanders bulkholderia cepasea or plasmodium falciparum, mycobacterium tuberculosis or vaccinia virus.The albumen that so produces can be arranged in array, as by every kind of albumen that will produce or peptide point sample on test surfaces such as chip.Can be by albumen and test surfaces, as with the non-specific binding of nitrocellulose, or, albumen is positioned on the described array by the association between the part on epi-position mark (if being present on albumen or the peptide) and the surface that combines the epi-position mark; For example, if albumen or peptide comprise polyhistidine tag, can use nickeliferous surface.

[0037] array can comprise a selected histone of described biology, or it can comprise and represent about at least 50%, 60%, 70%, 80%, 90%, 95% or 98% or more of infectious agent, i.e. the albumen and/or the peptide of full gene group substantially.The number of described albumen and/or peptide will be at least 100,200,300,400,500,1000,1500,2000 or surpass 2000 kinds of different sequences.In such embodiments, can gather some arrays independently of the bioprotein group of the described ratio of representative by preparation, thereby obtain described array.Therefore, in some embodiments, the invention provides the method in test surfaces production protein arrays, wherein this array is represented the selected part of the protein groups of infectious agent, at most and comprise whole substantially protein groups.Described protein groups array can be used for the strain of the pathogenic organisms of definite infected subjects, and is used to identify the immunodominance antigenic protein, or is used for any other activity or characteristic that definite albumen may have.In others, the present invention relates to and method that the antigen identified has immunoreactive monoclonal antibody and gives passive immunization with described antibody.

The accompanying drawing summary

[0038] Fig. 1 has shown the sketch of host's carrier and the nucleotide sequence around the BamH1 site.As shown in the figure, come from and insert the L-glutamic acid codon GAG that occurs in No. 206 bases in the segmental frame of genome pcr amplification.5 ' homologous clone district starts from base No. 206, and upstream extends 33 bases, and causes and the frame endomixis of 10 * histidine mark.3 ' homologous clone district starts from base No. 212, extends 33 bases downstream, causes the HA mark, and stops with the TAA terminator codon.

[0039] gel that shows of Fig. 2 showed clean from vaccinia virus and the native PCR product that draws hot Frances Salmonella.

[0040] Fig. 3 has shown the gel of the imitative cracked cell of phenol-nitrogen, and described cracked cell produces the total nucleic acid from the colibacillary overnight culture that realizes reorganization.

[0041] Fig. 4 has shown the plasmid of the micropreparation thing of the colony that the next overnight culture that adopts is selected in Fig. 3.

[0042] Fig. 5 has shown that the translation product to the plasmid micropreparation thing of Fig. 4 carries out electrophoretic SDS PAGE gel, surveys described gel with anti-polyhistidyl antibody.

[0043] Fig. 6 shows the Dot blot of translation product of the plasmid of the Fig. 4 that surveys with anti-Histidine antibody or anti-HA antibody.

[0044] Fig. 7 shows the demonstration result that has the SDS PAGE of the immunoreactive protein of identifying on the Dot blot with vaccinia virus immunoglobulin (Ig) (VIG) (Fig. 7 D) detection down with anti-histidine mark (Fig. 7), anti-HA mark (Fig. 7 B), with VIG (Fig. 7 C) that does not contain the intestinal bacteria lysate and lysate.

[0045] Fig. 8 show with and the quantitative result of the proteic Dot blot of each vaccinia virus when handling VIG without the intestinal bacteria lysate.

[0046] Fig. 9 shows and identifies the proteic microarray of vaccinia virus that has immunoreactive D8L, F13L, H3L, H5R, A56R and 644 with VIG.

[0047] Figure 10 has shown the total nucleic acid available from transformation mixture, and it comprises the insertion fragment from vaccinia virus mentioned above.

[0048] Figure 11 has shown the translation reaction of surveying with anti-polyhistidyl that carries out on available from the plasmid of cell mixture.

[0049] Figure 12 A-12D has shown the proteic Dot blot of Figure 11, and described albumen is applied on the nitrocellulose without purifying, to provide vaccinia virus proteic array.Figure 12 A-D has shown respectively when with anti-Histidine, anti-HA, result when the VIG that does not contain lysate, the VIG that contains lysate survey Dot blot.

[0050] Figure 13 has shown littler protein arrays, and it shows and the result when not having the intestinal bacteria lysate.

[0051] Figure 14 A and 14B have shown the vaccinia virus Dot blot result of not contacted antigen and vaccinia virus mice immunized and human serum.

[0052] Figure 15 has shown the scanning of the H3L envelope protein of vaccinia virus, wherein protein sequence is divided into 10 fragments, and overlapping 20 amino acid of the fragment that each fragment is adjacent are referring to the description of embodiment 8.

Implement pattern of the present invention

[0053] one embodiment of the invention provide the high throughput method of the array of the albumen that obtains representative encoded protein and/or peptide in the genome of infectious agent and/or peptide, make it possible to test the ability that this array causes body fluid and/or cellullar immunologic response.Proteic method in the preparation array is applicable to the albumen that generally prepares any source.Particularly, inherent high-throughput advantage is applicable to and provides from the albumen of infectious agent and the repertoire of peptide in this method.This method also can be used to provide multiple protein and/or the peptide by any nucleic acid encoding of known array, makes the part or the insertion fragment of each amplification to be offered the plasmid that can duplicate in containing the microorganism of recombinase.The described proteic method of preparation of the present invention is the DNA of its employing from the mixture extraction of microorganism with the difference of the method that adopted in the past, and the mixture of described microorganism is by cultivating transformation mixture rather than obtaining by separating single clone.This is favourable, because clone's separation causes obtaining the proteic natural form of mutant rather than needs usually.In addition, at screening stage, method of the present invention can adopt the not purified form available from the vector encoded of these mixtures and expressed proteins.Therefore, method of the present invention has significantly been simplified the automatization of general procedure, and has adopted high throughput processes.

[0054] adopt method of the present invention, can identify the specific protein from vaccinia virus, it will be effective vaccine.This is very significant, because the use of attenuated virus brings disadvantageous side effect sometimes.Preferably utilize single albumen or proteic definite mixture, rather than the complicated infectious agent of attenuation form.At present, for example, use hepatitis B virus surface antigen to realize this point.

[0055] as indicated above, method of the present invention is applicable to the nucleic acid (wherein known relevant nucleotide sequence) of encode generally multiple protein and peptide, the feasible segmental amplification of insertion that can need with suitable primer realization.As described in the US2003/0082579 and US2003/0044820 that are hereby incorporated by, the primer of design can comprise that the homologous recombination to needs provides the linking sequence of linearized vector.The primer self and/or the linearizing carrier that extend can provide suitable control sequence subsequently, as promotor and terminator, to realize expression and " mark ", as histidine mark, FLAG mark etc., to allow the reinforcement that combines with suitable solid surface, or if desired, allow the purifying of expressed proteins.Usually, also by the linearizing carrier of pcr amplification, rather than adopt more conventional vector digestion method, described ordinary method can obtain to contain and insert segmental carrier.

[0056] in group method of the present invention, coding multiple protein or peptide, and the known nucleic acid molecule of nucleotide sequence as the infectious agent genome, are used as substrate.With increase the separately fragment of (promptly in single reaction mixture) each coding protein of interest or peptide of PCR or other amplification technique, wherein adopt and contain and terminal portions complementary sequence of encoding sequence and can coded markings and/or the adapter of the sequence expressed of control, but, its in anything part all with linearization plasmid on the sequence homology that provides.Then, the fragment of amplification separately and linearizing plasmid co-transfection in the microorganism that contains recombinase, are recombinated in the body carrying out.The biology that contains recombinase can be that for example, yeast maybe can be chemoreception attitude intestinal bacteria (or secondly ideal is electroporation competence intestinal bacteria).Suitable chemoreception attitude intestinal bacteria comprise bacterial strain JC8679, TB1, DH5 α, HB101, JM101, JM109 and LE392.Saccharomyces cerevisiae is the yeast that especially effectively contains recombinase.

[0057] ratio of DNA and cell can be up to 1,000,000 cells of 100ng/ in the transfection reaction; But the ratio that is low to moderate 1-10ng, 5-10ng, 1-5ng or 1,000,000 cells of 1-3ng/ also can be used.Usually need provide linearizing plasmid, the ideal nucleotide sequence is about 1: 1 mol ratio, but also can use 5: 1 to 10: 1 to 100: 1 ratio, also can be to use 1: 5 to 1: 10 to 1: 100 ratio.

[0058] handles cell with the insertion fragment of amplification thus, on suitable medium, cultivate the linearized vector of amplification, usually overnight incubation.Obtained the mixture of cell, great majority contain the recombinant vectors of needs, and described carrier has the fragment of the amplification of the required nucleotide sequence that inserts with correct direction.(guaranteeing directivity with the homology part of coupling linearization plasmid) by the design primer.Directly obtain plasmid DNA, rather than separate single colony,, and help obtaining mutant because separate the segmental risk of insertion that single colony has the loss needs from culture harvested cell and extraction.By proper host cell is arrived in the DNA transfection, perhaps, in external translating system, make plasmid mixture transcribe/translate then usually in order to reach high-throughput.Described external translating system is commercially available, and the method for using them is well known to a person skilled in the art.Then, can be directly with the albumen that obtains or peptide point sample on solid support, described upholder can be albumen and the array of peptide, the hole of described surface such as microtiter plate or the sectional nitrocellulose in any suitable surface preparation.If desired, purifying protein perhaps adopts from primer or plasmid-encoded mark purifying protein to albumen by means commonly known in the art, perhaps, can directly use and transcribe/translate mixture, and not be further purified albumen, so that provide albumen or peptide to solid support.By the purifying of this method production or the albumen of basic purifying is an aspect of of the present present invention.These albumen or peptide can be naturally occurring peptides, or comprise one or more interpolations, the modified forms of epi-position mark as described further below.When albumen is attached to upholder, the corresponding part of the mark on albumen or the peptide is provided for solid support self.

[0059] in order to obtain proteic array, the step that the ORF that needs number or its part are carried out aforementioned order.If for any screening of carrying out on array, possible material standed for is known, only obtaining relatively small number target protein or peptide may be favourable as the member of albumen/peptide array.But, can change multiple nucleotide sequence into albumen or peptide; As many as 50,100,500,1,000 or more.For example, if adopt the genome of infectious agent, or any procaryotic genome, array can comprise at least 10%, 20%, 50%, 75%, 90%, 95% or 100% expressed proteins and peptide.The array that obtains can be represented biological complete substantially protein groups, promptly at least about 98% protein groups or its part only, maybe can represent the proteic single peptide moiety in the protein groups, the combination of full-length proteins and partial sequence.

[0060] in order to promote the preparation of peptide or proteic array, maybe advantageously with interested peptide or albumen and the fusion of small peptide mark, the common length of described mark is 6-20 amino acid, and it is incorporated into the particular functional group.Then, described bonding mark can be used for purifying protein or with proteopexy in test surfaces, or detect proteic existence.The described bonding mark of being made up of short aminoacid sequence is known, so-called epi-position mark.For example, by suitable nucleotide sequence being mixed the adapter that is used for genomic nucleic acids is inserted expression plasmid, can (10 amino acid whose fragments of people's proto-oncogene myc EQKLISEEDL) be blended in peptide or the albumen that will express with hemagglutinin (HA) epi-position mark (as human influenza virus's hemagglutinin YPYDVPDYA) or c-Myc epi-position mark.Then, can use the antibody test of c-Myc, HA or other epi-position mark or the peptide of localization and expression.

[0061] similarly, polyhistidine tag can be used as the epi-position mark, and can mix in the expressed proteins by the appropriate designs of adapter, and described adapter is used for genomic nucleic acids is inserted the carrier that is used for expressing protein.Polyhistidyl epi-position mark can comprise 3-12 histidine residues continuously, usually 6-10 continuous histidine residues.Described polyhistidine tag is with specificity and combining closely in nickel surface; Thus, contain the peptide of expression of described mark or albumen and will combine closely in the surface of nickel bead, nickel bag quilt or comprise nickel or nickel salt or complex compound, as the affinity column of nitrilotriacetic acid(NTA) nickel (Ni-NTA).Therefore, by with nickel or nickel salt or complex compound bag by each hole, then the solution of every kind of albumen or peptide is placed the hole of described nickel bag quilt, and makes proteopexy in the surface, contain the albumen of polyhistidine tag or the array of peptide with 96 well format productions.Similarly,, or, described albumen can be attached to pearl, be used for showing easily by be coated with the pearl of other material with nickel or nickel salt or complex compound by the preparation nickel bead.In one embodiment, genomic albumen is carried out mark, make it be attached to the nickel bead of 1um with the polyhistidine tag that comprises at least 6 continuous histidine residues; Then these pearls are used to measure the immunne response of T cell, as the hereinafter description of embodiment 9.

When [0062] needing, also can connect two kinds of different marks: the nucleotide sequence of first mark of encoding, it can be included near the 5 ' end of the nucleic acid that inserts plasmid, so that N-terminal linkage flag in expressed proteins, nucleotide sequence with coding second mark, it can be included near the 3 ' end of the nucleic acid that inserts plasmid, so that in the C-terminal linkage flag of expressed proteins.These marks can be identical, to guarantee being covered identification under the therefore unreachable situation when end; Or they may be different, to guarantee to use two kinds of different catching or detection method.Be used to detect, other mark of location or purifying also can be connected in genome albumen as required.Described mark comprises glutathione-S-transferase (GST), biotinylation signal, green fluorescent protein (GFP) etc., can mix each described mark by means commonly known in the art.

[0063] in a single day obtained the peptide/albumen or the peptide/proteic array that need, can screen, obtained the characteristic or the reactivity of any needs it.Example of described purposes is screening immune-active peptides and albumen.Immunocompetence can be at body fluid or cell system.Under any situation, need to obtain from what the experimenter who is exposed to infectious agent or its some parts obtained to sieve to select agent.Randomly, can screen the array of albumen or peptide with the one or more immunizing compositions that come from a plurality of experimenters (serum, phlegm, blood plasma, T cell etc.), described experimenter all has been exposed to infectious agent or its part, as its envelope protein or cracked cell, or its a kind of or multiple protein.Immunne response which antigen induction this has made it possible to determine among a plurality of experimenters, wherein general knowledge other those is called immunodominance antigen.The antigen of a family can be used for the serodiagnosis test or be used to comprise the antigenic vaccine of some described immunodominances.

[0064] method of the present invention goes for the several genes group, and is applicable to infectious agent usually, comprises the genome of virus, fungi, bacterium, protozoon etc. and many cells parasite such as flatworm, fluke, roundworm etc.By the proteic array that provides rapid production to represent most of or all protein groups of described infectious agent, the invention enables and to identify rapidly for the vaccine or the most useful those genes and the albumen of diagnostic test of exploitation at specific infectious agent.

[0065] therefore, the term of herein using " immunocompetence " is the ability of finger protein or inducing peptide immunne response, described body fluid or the cell response of replying no matter, or the two.Humoral immunoresponse(HI) is a kind of acquired immunity mechanism, it is characterized in that production of antibodies, and cellullar immunologic response is characterised in that generation and/or activation such as the cell of activated NK cell (NK) cell and cytotoxic T lymphocyte (T cell or CTL).Similarly, " antigen " is meant described immunoreactive protein or peptide, no matter and the character of inductive immunne response how." immunodominance antigen " is meant the antigen of induce immune response in being exposed to antigenic great majority or all experimenters; Described immunodominance antigen most possibly is provided for the inductor that vaccine composition in the passive immunization method or antibody produce, and is therefore particularly useful for the composition as immune composition, and also can be used for the serodiagnosis test.

[0066] peptide of other cell surface of T cell recognition/MHC mixture.The so-called antigen presenting cell of described cell (APCs).Although the effector cell can be by described compound-mediated their function of identification on any substantially cell type, by the APCs of one group of specialization, promptly the not contacted antigenic cell of dendritic cell (DCs) is activated most effectively.

[0067] " array " used is meant the set that systematically is positioned at the material at least one test surfaces herein, comprises the material that is included in the hole that forms on the described surface or the depression, and wherein the placement of this material is relevant with the identity of material.Array comprises the materials of so placing at least about 10 kinds usually, comprises at least 100 or 200 or 500 kind usually, maybe can comprise 1000 or more kinds of material.It comprises the material of point sample on chip, plate or nitrocellulose matrix, for example, is included in the material in the hole of 96 holes and 384 orifice plates and similar plate, as long as these materials are retained in the position of placing them, no matter be owing to physics or chemical force keeps.Array can comprise a plurality of plates, chip or other surface.Microarray is a kind of array of microminiaturization, and for example, they can be designed as and make the reagent volume minimum.Although array described herein is the array of antigenic peptide normally, the present invention includes the array that has antibody selective for described peptide.

[0068] antigen identified of method of the present invention can be peptide or albumen, and can be used to prepare the immunogenic composition that protection experimenter anti-infection agent infects, or produces and be used to provide passive immunization or be used for purifying or detect antigenic monoclonal antibody.Described immunogenic composition can be to induce the experimenter to produce immunne response, and as the vaccine of generation antibody, or they self can provide the antibody or the active immne material of passive immunization.The antiidiotypic antibody or the nucleic acid that produce them can be used to replace antigen.They also can be the nucleic acid vaccines that produces one or more antigenic epitopes, and its amplifying nucleic acid can be by experimenter's self cellular uptake.They can the accompaniment functions element, as the promotor of the generation of the antigenic protein of realizing coding or peptide, maybe can be naked DNA.

[0069] the present invention also comprises and peptide and basic homologous peptide of antigen and the antigen identified by method of the present invention, and derives from the antigenic immune composition of described basic homologous.Therefore, the present invention includes peptide or the basic homologous peptide of albumen or proteic diagnostic test or the vaccine that contains with by method evaluation described herein; The present invention includes and the antigenic specific antibody of identifying by method described herein of the basic homologous of antigen; And the present invention includes nucleic acid with these basic homologous peptides of coding or proteic nucleotide sequence.

[0070] represents albumen or peptide at the term " basic homology " of albumen or peptide use herein corresponding to reference protein or peptide, wherein said albumen or peptide have and the essentially identical 26S Proteasome Structure and Function of reference substance, for example, only be the change of aminoacid sequence, do not influence function.Therefore, in this application, basic homologous peptide and albumen are immunocompetent, and have similar structure to reference substance.As for structure, the identity per-cent between basic homologous albumen or peptide and reference protein or the peptide is at least 65%, or at least 75%, or at least 85%, or at least 90%, or at least 95%, or at least 99%.

[0071] can be used for identity protein sequence comparison relatively by means commonly known in the art.Relatively the process useful of protein sequence comprises Smith﹠amp; Waterman, local homology's algorithm of Adv.Appl.Math.2:482 (1981); Needleman﹠amp; Wunsch, the homology alignment algorithm of J.MoI.Biol.48:443 (1970); Pearson﹠amp; Lipman, the similarity method retrieval of Proc.Natl.Acad.Sci.USA 85:2444 (1988); (GAP in the Wisconsin Genetics software package, BESTFIT, FASTA are implemented in the computerize of these algorithms, and TFASTA, Genetics Computer Group, 575 Science Dr., Madison, Wis.) and visual observations (the Ausubel et al that vide infra usually and quote).

[0072] example that is suitable for determining the algorithm of sequence identity and sequence similarity per-cent is the BLAST algorithm, and it is described in Altschul et al, J.Mol.Biol.215:403-410 (1990).The software that carries out the BLAST analysis can be from the website of NCBI Www.ncbi.nlm.nih.govThe open acquisition.This algorithm relates to that the short word that at first is tested and appraised length W in the inquiry sequence is long identifies high sub-sequence to (HSPs), described inquiry sequence when with database sequence in during identical word length comparison, mate or satisfy some on the occasion of the threshold value score.T is called adjacent words score threshold value (Altschul et al, 1990).These initial adjacent words are hit the seed as the retrieval of the longer HSPs that start to find to contain them.Then, extend word along the both direction of each sequence and hit, up to increasing cumulative comparison score.For nucleotide sequence, the cumulative scoring is (for the award scoring of a pair of coupling residue with parameter M; Always＞0) and N (for the point penalty of mispairing residue; Always＜0) calculate.For aminoacid sequence, calculate the accumulation score with rating matrix.When the amount that descends from its maximum value that reaches when cumulative comparison score was X, the extension that the word of each direction hits stopped, the cumulative score reach 0 or below, this is because the accumulation that the one or more residues that must bear branchs are compared, or reaches the end of arbitrary sequence.BLAST algorithm parameter W, T and X have determined the sensitivity and the speed of comparison.For aminoacid sequence, the default value that the BLASTP program adopts is that word length (W) is 3, and desired value (E) is 10, and the BLOSUM62 rating matrix is (referring to Henikoff﹠amp; Henikoff, Proc.Natl.Acad.Sci.USA (1989) 89:10915).

[0073] (Megalign program Wis.) is carried out sequence alignment for DNASTARInc., Madison can to use LASERGENE information biology computation program group.Can comparing method (Higgins and Sharp (1989) CABIOS.5:151-153) with Clustal, to carry out the multiple ratio of sequence right, wherein adopts default parameters (GAP PENALTY=10, GAP LENGTHPENALTY=10).The default parameters that pursues comparison with the Clustal method can be KTUPLE1 for example, GAP PENALTY=3, WINDOW=5 and DIAGONALSSAVED=5.

[0074] or, when albumen or peptide are that immunity intersects when sending out answering property, consider that albumen or peptide also are basic homologous.Can be with the form selection of panimmunity mensuration and specific protein or the immunoreactive antibody of peptide specific.For example, conventional solid phase ELISA immunoassay, Western blot or the immunohistochemical methods of using selected and the immunoreactive monoclonal antibody of protein-specific.For the immunoassay form and the condition that can be used for determining specific immune response, referring to Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring HarborPublications, New York " Harlow and Lane ").Typically, specificity or selective reaction will be background signal or noise at least 2 times, more typical be surpass background 10-100 doubly.

[0075] one of ordinary skill in the art will appreciate that, the amino acid of change in the sequence, interpolation or disappearance single amino acids or little per-cent (for example, less than about 5%, or for example less than about 1%) each replacement, disappearance or interpolation be " conservative modify variation ", wherein said change causes with chemically similar aminoacid replacement amino acid.It is well known in the art that amino acid whose conservative replacement table similar on the function is provided.Below five groups all comprise each other the conservative amino acid that replaces: aliphatic amino acid: glycine (G), L-Ala (A), Xie Ansuan (V), leucine (L), Isoleucine (I); Aromatic amino acid: phenylalanine (F), tyrosine (Y), tryptophane (W); Sulfur-containing amino acid: methionine(Met) (M), halfcystine (C); Basic aminoacids: arginine (R), Methionin (K), Histidine (H); Acidic amino acid: aspartic acid (D), L-glutamic acid (E), l-asparagine (N), glutamine (Q).Also referring to Creighton (1984) Proteins, W.H.Freeman andCompany.The variation of the nucleotide sequence of the sequence of each description nucleic acid of describing in secret or the conservative modification of amino acid sequence of polypeptide.

[0076] an aspect of of the present present invention relates to the nucleotide sequence of the whole or major portion of coding specific amino acids sequence, the albumen that described specific amino acids sequence encoding is identified or its major portion herein.(a described proteic example is that the H3L west keeps strain, the strain of H3L Copenhagen and H3L smallpox Bangladesh strain albumen).The aminoacid sequence that enough provides predictive to identify is provided proteic " major portion ", described evaluation is by the manual evaluation of those skilled in the art to sequence, or the sequence by computer automation relatively and identify that it adopts (the basic part comparison gopher such as BLAST; Altschul, S.F., et at, (1993) J.MoI.Biol.215:403-410) algorithm.In general, the sequence of 9 or more continuous amino acids identifies that for predictive a kind of albumen and known protein homology are necessary.The identity per-cent of the aminoacid sequence that can compare with disclosed albumen herein by fragment is identified basic homologous protein fragments.

[0077] as more detailed pointing out hereinafter, can synthesize the preparation immunogenic peptide, as by chemosynthesis or by recombinant DNA technology, or from natural origin such as intact virus or other infectious agent separating immune originality peptide.Although peptide does not contain other naturally occurring host cell proteins and fragment thereof usually substantially, in certain embodiments, peptide can be puted together synthetically with natural fragment or clone.

[0078] can modify as required and have required active peptide,,, increase or keep at least substantially all antigenicity activity of unmodified peptide simultaneously as improved pharmacological characteristic with the characteristic that provides some to need.For example, peptide can carry out multiple change, and as conservative or non-conservative replacement, wherein said change provides some benefit may for their purposes, as improved MHC combination.The scope of aminoacid replacement also can comprise uses D-amino acid.Can carry out described modification with known peptide synthesis program, as Merrifield, Science 232:341-347 (1986), Baranyand Merrifield, The Peptides, Gross and Meienhofer, eds. (N.Y., Academic Press), pp.1-284 (1979); With Stewart and Young, Solid PhasePeptide Synthesis, (Pierce), the description among the 2d Ed. (1984) is incorporated herein above-mentioned every piece of document as a reference for Rockford, IlI..

[0079] pharmaceutical composition of being used for the treatment of property processing is intended to be used for parenteral, surface, oral or topical.The composition that may in pharmaceutical composition of the present invention, comprise in some embodiments, at least a CTL of exciting.Identified lipid and be the reagent that excites antiviral antigenic CTL in can body.For example, palmitic acid residues can be connected in the α and the ε amino of Lys residue, for example by one or more connection residues, is connected in immunogenic peptide as Gly, Gly-Gly-, Ser, Ser-Ser etc. then.Then can with the peptide of liposomeization with the micelle form direct injection, mix in the liposome or be emulsified in the adjuvant such as Freund's incomplete adjuvant.In one embodiment, especially effectively the immunogen bag is connected in the α of Lys and the palmitinic acid of ε amino, and described Lys is connected in the N-terminal of immunogenic peptide by the key such as Ser-Ser.

[0080] can prepare peptide of the present invention by number of ways.Because they are short relatively, can be according to routine techniques, more synthetic such peptides (discrete epi-position or multi-epitope peptide) in solution or on solid support.Multiple automatization synthesizer is commercially available, and can use according to known scheme.Referring to, for example, Stewart and Young, Solid Phase PeptideSynthesis, 2d.ed., Pierce Chemical Co. (1984) is hereby incorporated by.

[0081] peptide of the present invention and medicine thereof and vaccine composition can give Mammals, particularly people, so that therapeutic treatment and/or preventing infection.For pharmaceutical composition, immunogenic peptide of the present invention gives to have infected the individuality of interested infectious agent usually.Can be as required, with handling the infection of latent period or acute phase separately or with immunogenic peptide of other treatment associating.In treatment is used, give the patient composition, present in an amount at least sufficient to induce the antigenic effective CTL of infectious agent is replied and cures or to small part relief of symptoms and/or complication.Be enough to realize that the amount of this purpose is defined as " treatment effective dose " or " unitary dose ".For this reason the significant quantity of purposes depend on usually for example peptide composition, administering mode, treatment disease by stages with severity, patient's body weight and general health situation, prescription doctor's judgement.Usually for the mankind, the dosage range of initial immunity (be used for the treatment of or prevent administration) is about 1.0 μ g-about 20 for the patient of 70kg, 000 μ g peptide, about typically 50 μ g, 100 μ g, 150 μ g, 200 μ g, 250 μ g, 300 μ g, 400 μ g or 500 μ g, 1000 μ g, 2000 μ g, 5,000 μ g, 10,000 μ g, 15,000 μ g or 20,000 μ g, sometimes give the booster dose of same dose scope subsequently, but actual dose is not necessarily identical, reinforcement is according to strengthened scheme, carry out several weeks to the several months, this depends on by measuring active reaction and the situation of determining of specific CTL in the blood samples of patients.

[0082] patient who treats with described vaccine composition and the patient group that prevents administration with described vaccine composition determine well known to a person skilled in the art.For therepic use, should infect the back short period of time and begin administration occur infecting sign or diagnosing acute first.Give booster dose subsequently, up to symptom basically eliminate and for some time subsequently at least.In chronic infection, may need to load dosage and booster dose subsequently.

[0083] also peptide combinations can be used for the treatment of chronic infection and stimulating immune system, to eliminate the cell that is infected by the virus among the carrier for example.The peptide of the immune strengthening amount in the preparation is provided and is enough to the mode of administration that the effective stimulus cytotoxic T cell replys normally important.Therefore, for the treatment chronic infection, may need to give immunizing dose, the interval to determine as 1-4 week, gives booster dose then, preferably gives for a long time, with effective immune body.

[0084] common, need preparation to contain at least two kinds or at least three kinds or five kinds or more kinds of antigenic cocktail, so that guarantee that vaccine is effective for the recipient of wide region from infectious agent.Except the main antigenicity activity of peptide, it is used for also sometimes determining whether non-immune experimenter also shows the immunne response to peptide.As the cocktail of the immunogenic peptide of vaccine selected sometimes comprise at least two kinds or at least three kinds with from the experimenter's of immunity sero-reaction but not with albumen from non-immune experimenter's sero-reaction.

[0085] any method that can be familiar with by those skilled in the art comprises that oral, suction, surface and injecting method send to pass composition of the present invention.Usually, parenteral gives pharmaceutical composition, gives as intravenously, subcutaneous, intracutaneous or intramuscular.Therefore, the invention provides the composition that is used for administered parenterally, it comprises and is dissolved in or is suspended in acceptable carrier, the solution of the immunogenic peptide in the preferred aqueous carrier.Can use multiple aqueous carrier, as water, damping fluid, 0.8% salt solution, 0.3% glycine, hyaluronic acid etc.Can sterilize to composition by the known sterilising technology of routine, maybe can carry out sterile filtration.The aqueous solution that obtains can be packed, use or freeze-drying with original form, freeze-dried preparation mixes with sterile solution before administration.Composition can contain pharmaceutically useful auxiliary substance according to the needs of roughly physiological situation, as pH regulator agent and buffer reagent, osmotic pressure regulator, wetting agent etc., for example sodium ethylene diamine tetracetate, Sodium.alpha.-hydroxypropionate, sodium-chlor, Repone K, calcium chloride, sorbitanic one lauric acid ester, Emulphor FM etc.

[0086] also can give composition of the present invention by liposome.Liposome comprises milk sap, foam, micella, insoluble monolayer, liquid crystal, phosphatide dispersion, thin layer etc.In these preparations, mixed and to have sent the peptide formulations passed a part as liposome, described peptide be independent or with for example be incorporated into the molecule of ubiquitous acceptor or other treatment or immunogenic composition combination in lymphoidocyte, described molecule is as being incorporated into the antigenic monoclonal antibody of CD45.Therefore, can be with the liposome that the peptide of needs of the present invention has carried out filling or modifying at the site of lymphoidocyte, liposome can send herein and pass selected therapeutic/immunogenicity peptide combinations then.Be used for liposome of the present invention and be forming from the lipid of the formation vacuole of standard, described lipid generally includes neutral and electronegative phosphatide and sterol, as cholesterol.The selection of lipid is usually according to following consideration, as liposome size, acid labile and the liposome stability in blood flow.Several different methods can be used to prepare liposome, as Szoka, and et al., Ann.Rev.Biophys.Bioeng.9:467 (1980), United States Patent(USP) Nos. 4,235, the description in 871,4,501,728,4,837,028 and 5,019,369.Also can use the adjuvant and the milk sap of other type, as SAF-1, PROVAX and tomatine.Also can use the albumen or the antigenic immunne response of peptide of the anti-preparationization of alum secondary stimulus.

[0087] for solids composition, can adopt conventional non-toxic solid carrier, for example, the N.F,USP MANNITOL of pharmaceutical grade, lactose, starch, Magnesium Stearate, soluble saccharin, talcum powder, Mierocrystalline cellulose, glucose, sucrose, magnesiumcarbonate etc.For oral administration, by mixing the vehicle that adopts under any normal circumstances, as carrier listed earlier, activeconstituents with common 0.01-95%, be one or more peptides of the present invention and prepare pharmaceutically useful non-toxic composite, the preferred concentration of described activeconstituents is 0.1%-75% or 0.2%-50% or 1%-20%.

[0088] for aerosol drug delivery, the form with fine segmentation provides immunogenic peptide with tensio-active agent and propelling agent usually.The exemplary percentages of peptide is 0.01 weight %-20 weight % or l weight %-10 weight %.Certainly, tensio-active agent must be nontoxic, is soluble usually in propelling agent.The representative of described reagent is ester or the part ester that contains the lipid acid of 6-22 carbon atom and aliphatic polyol formation, or its cyclic anhydride, described lipid acid such as caproic acid, sad, lauric acid, palmitinic acid, stearic acid, linolic acid, linolenic acid, olesteric acid and oleic acid.Can adopt mixed ester, as mixing or natural glyceryl ester.Tensio-active agent can account for 1 weight %-20 weight % of composition, common 0.25 weight %-5 weight %.The normally propelling agent of composition.Also can comprise carrier as required, pass for sending in the nose, as Yelkin TTS.

[0089] peptide of the present invention also can be by attenuated virus host such as vaccinia virus or fowlpox virus expression.This method relates to the carrier of vaccinia virus as the nucleotide sequence of expressing coding peptide of the present invention.The vaccinia virus vector and the method that are used for immunization protocol are described in for example U.S. Patent No. 4,722,848.Another kind of carrier is BCG (Bacille Calmette Guerin).The BCG carrier is described in for example Stover, and et al. (Nature 351:456-460 (1991)) is hereby incorporated by.According to explanation herein, it will be appreciated by those skilled in the art that multiple other carrier of the therapeutic administration that can be used for peptide of the present invention or immunity, as the salmonella typhi carrier etc.

[0090], can give peptide of the present invention with the form of nucleic acid of one or more peptides of the present invention of coding for treatment or immune purpose.Nucleic acid can encode peptide of the present invention and optional one or more extra molecules of coding.Routine is sent nucleic acid in many ways and is passed the patient.For example, nucleic acid directly can be sent as " naked DNA " and pass.This method is described in for example Wolff, et al, and Science 247:1465-1468 (1990) and United States Patent(USP) Nos. 5,580,859 and 5,589,466 are hereby incorporated by.Can send to pass with trajectory according to the description in the U.S. Patent No. 5,204,253 for example and give nucleic acid.Can give the complete particle of forming by DNA.Perhaps, DNA can be adhered to particle, as gold grain.Pass as for sending of peptide, usually need preparation to contain the cocktail that at least two kinds, at least three kinds or five kinds or more kinds of coding come from the antigenic peptide that infects species, effective to guarantee DNA to the recipient of wide region.

[0091] also nucleic acid and cation compound such as compound the sending of cation lipid can be passed.The gene delivery method of lipid mediation is described in for example WO 96/18372; WO 93/24640; Mannino﹠amp; Gould-Fogerite, BioTechniques 6 (7): 682-691 (1988); Rose U.S. Patent No. 5,279,833; WO 91/06309; And Feigner, et al, Proc.Natl.Acad.Sd.USA 84:7413-7414 (1987) is hereby incorporated by.

[0092] can prepare the plasmid DNA of purifying, be used to adopt several formulations to inject.The simplest in these methods is in aseptic phosphoric acid buffer (PBS) freeze dried DNA to be carried out reprovision.Describe several different methods, and can obtain a lot of new technologies.As indicated above, nucleic acid is normally prepared with cation lipid.In addition; being referred to as protectiveness, the sugar ester of interactional, non-cohesion (PINC), the liposome that causes fusion, peptide and compound also can be compound with plasmid DNA purification; influencing various variablees, disperse or be transported to certain organs or cell type as stability, intramuscular.

[0093] immunogenic composition will contain the antigen of one or more evaluations of significant quantity and suitable vehicle.The injection vaccine will typically contain vehicle and give other composition of stability.The character of composition will depend on route of administration, and described approach can be for example intravenously, intramuscular, subcutaneous or peritoneal injection, maybe can be through mucous membrane, through skin or mouthful group.The design that is used for the composition of vaccine is fully established, and be described in for example Remington ' sPharmaceutical Sciences, latest edition, Mack Publishing Co., Easton, the book of PA and Plotkin and Orenstein " vaccine " by name, the 4th edition, Saunders, Philadelphia, PA (2004) is hereby incorporated by.

[0094] virion with deactivation is opposite, carries out immunity with single albumen, may need adjuvant, so that induce strong immune response.Although mineral oil may be enough, reported that the use by the stable squalene milk sap of the linear amphiphilic polymer that is called the pluronic polyvalent alcohol is more superior for induce immune response.Referring to Hunter, et al, Vaccine, 20 Suppl.3, S7-12 (2002) is hereby incorporated by.In addition, Liposomal formulation can be advantageously used in increase to proteic immunne response.Referring to Lidgate, et al, Pharm.Research, 5, pg.759-764 (1988); Hjorth, et al, Vaccine 15, and 541-46 (1997) is hereby incorporated by.The universal method and the scheme that give vaccine also are described in Plotkin and Orenstein, Vaccines, the 4th edition.

[0095] also can be used for diagnostic purpose and be used for administration by antigen provided by the invention with induction of immunity.Can with by aforesaid method is identified one or more or two or more, or the specific reaction of preferred three kinds or multiple specific antigens detects the antibody of infectious agent or quantitatively, and this makes it possible to the described infectious agent among the infected experimenter of Rapid identification and the particular strain of infectious agent.Antigenic array can be used for very accurately distinguishing the specific bacterial strain of infectious agent.Infectious agent among the experimenter that this makes it possible to even detection exposes before symptom occurring.This allows to determine whether the experimenter has the immunity to specific infectious agent, so can avoid unnecessary immunity.This makes it possible to also identify that antibiotic-resistant bacteria infects or the antiviral resistance virus infection, for example, allows the doctor to avoid giving invalid medicine thus, and can select suitable medicine or treatment fast.In addition, make the user can identify particular disease states: the serum curve with patient of chronic tuberculosis will be different from and have the new or active patient who infects, and therefore, the antigen that adopts diagnostic of the present invention to provide can more accurate evaluation morbid state.

[0096] the present invention also comprises the array of proteic antibody of the present invention and described antibody.Antibody can for example, be prepared in the laboratory animal such as rabbit, mouse or domestic dog by prepared by any suitable process.Comprising proteic antigen of the present invention can mix with incomplete Freund's adjuvant, adsorbed onto alum adjuvant, or does not mix (only being PBS) with adjuvant, and is expelled in the laboratory animal with one or more injection liquids.Any type of antigen may be used to produce antibody, so that enough produce the specific antibody of specific antigen.Inducibility antigen can be separately or with single epi-position, a plurality of epi-position of one or more immunogenicity tougheners combinations well known in the art, or intact proteins.Inducibility antigen can be isolating full-length proteins, cell surface protein (as using the immunity of at least a portion antigen cells transfected), or soluble protein (as only using proteic extracellular domain partial immunity).

[0097] as use herein " antibody " be meant complete immunoglobulin (Ig) and as described in the immunogenic response fragment of antibody, as Fab, Fab ', F (ab ' ₂), the strand variable region that produces of fragment, reorganization, i.e. sFv form and any other fragment that can the specific recognition epi-position.

[0098] in some embodiments, preferred monoclonal antibody.The preparation monoclonal antibody method is well known in the art, and briefly is described in Janeway, et al, and Immunobiology, the 5th edition, Garland Publishing, New York, NY (2001) is hereby incorporated by.Sessile antibody is well known in the art with the method for preparing array, as is applied to the retentivity surface such as nitrocellulose.

[0099] can screen the combining of normal or phenotype variant form of antibody and antigenic protein.Referring to, for example, ANTIBODY ENGINEERING:A PRACTICALAPPROACH (Oxford University Press, 1996) is hereby incorporated by.These monoclonal antibodies will more generally be at least about 300nM, typically at least about 30nM, usually at least about 10nM, usually at least about 3nM or better K with at least about 1 μ M usually _dIn conjunction with, described K _dNormally determine by ELISA.Comprised those (promptly comprising part) of chimeric form or the humanization form that produces by standard humanization or experimenter's adaptive technique in the definition of monoclonal antibody, or be suitable for the form of particular subject from the heavy chain and the light chain of different plant species.

[0100] antibody provided herein can be used for diagnostic use, and gives passive immunization.They comprise the separation antibody of generation and with the partially purified at least antibody of method well known in the art.These antibody can be used for infectious agent is detected or quantitatively, antigen obtains from described infectious agent; For example, they can be used for detecting the biological weapon infectious agent of experimenter or the contaminated material of possibility, because can produce them from new strain very apace.They also can be used in order to treat or epidemiology purpose and distinguish the bacterial strain of infectious agent, or identify such as those to certain drug responsive or insensitive specific bacterial strain.The array of antibody can be used to identify the particular strain of infectious agent.Antibody is the useful reagent of antigen purification.

[0101] provides following examples to illustrate rather than limited the present invention.In these embodiments, the vaccinia virus strain of use is the WR strain.The sequence of the genomic open reading-frame (ORF) of this strain is preserved in GenBank with the VACWR title that has numeral.The tabulation of the locus of open reading-frame (ORF) sees Table 8, after table 8 is listed in embodiment.List in the WR strain in the table 8 open reading-frame (ORF) directly to homologue (it is present in the strain of Copenhagen) also by their Sequence Identification in GenBank, wherein they have the title shown in the 2nd row of table 8.

[0102] as can be seen, a locus in the WR strain, promptly VACWR148 does not have respective straight in the strain of Copenhagen to homologue; Its part is corresponding to the antigen with title A29L in the smallpox, and is to identify so at first.Further observe in detail, WR148 demonstrates strong immunodominance antigenicity reaction, but is not plotted on the individual gene in the relevant species.On the contrary, WR146, WR147, WR148 and WR149 gene are corresponding to A type inclusion body protein groups or ATI locus albumen.The ATI locus is corresponding to A26L in the cowpox and A27L, and the A26L in the smallpox, A27L, A28L, A29L and A30L.

[0103] in embodiment and claim, for antigenic other gene of VACWR148 and gene product, and ATI locus gene or ATI locus albumen have used corresponding to Copenhagen directly to the name of homologue.Can find in the table 8 and be used for embodiment and the dependency WR strain.

Embodiment 1

Preparation carrier and insertion fragment

[0104] digests the linear T7 carrier for preparing coding N-terminal histidine mark and C-terminal HA mark with PCR subsequently by wide limits; Do not enter when transforming under the colibacillary situation of chemoreception attitude there being complementary to insert fragment, this program makes the amount of residual circular vectors and background colony be reduced to approaching.

[0105] plasmid that is used to prepare linear recombinant vectors pXT7 is shown in Fig. 1.This carrier comprises the T7 promotor, is thereafter ATG initiator codon, 10 * Histidine sequence, intervening sequence, BamH1 site and the T7 terminator of first codon front of the open reading-frame (ORF) that will clone.This carrier is a double digestion in the BamH1 site, to eliminate residual circular vectors, inserts segmental background colony because the carrier of incomplete digestion produces to lack.By this linearizing carrier of pcr amplification, to produce the storage of linear recombinant vectors.Every batch of linear carrier is transformed in the competence intestinal bacteria, does not produce the background colony to confirm it.

[0106] in more detail, with BamH1 (0.1 μ g/ μ l DNA, 0.1mg/ml BSA, 0.2U/ μ lBamH1,37 ℃, 4 h; Extra BamH1 is added to 0.4U/ μ l, 37 ℃, spends the night) to plasmid pXT7 (10 μ g; 3.2kb, KanR) carry out linearizing.Purifying (Qiagen PCR purification kit) digest, quantitative by photofluorometer, and by agarose gel electrophoresis (1 μ g) confirmation.This material of 1 nanogram is used for (primer, each 0.5 μ M:5 ' CTACCCATACGATGTTCCGGATTAC, 5 ' CTCGAGCATATGCTTGTCGTCGTCG at 50 μ l-PCR; 0.02U/ μ l Taq archaeal dna polymerase [Fisher Scientific, buffer A]; 0.1mg/ml [come from pig, Bloom 300 for gelatin; Sigma, G-1890]; 0.2mM every kind of dNTP; Initial sex change: 95 ℃, 5 minutes; 30 circulations: 95 ℃, 0.5 minute/50 ℃, 0.5 minute/72 ℃, 3.5 minutes; The final extension: 72 ℃, 10 minutes) the preparation linearity is accepted carrier in.Observe the PCR product by agarose gel electrophoresis (3 μ l), purifying (Qiagen PCR purification kit), and undertaken quantitatively by the fluorescence art with picogreen (Molecular Probes) according to the specification sheets of manufacturers.Check that every batch of linearity accepts the background KanR transformant (every 40ng does not have the KanR transformant) in the carrier.

[0107] draw the ORF of hot Frances Salmonella, described primer to contain extension with 33 Nucleotide of terminal complementary of linear T7 carrier with gene-specific primer amplification from vaccinia virus and soil.

[0108] in 50 μ l-PCR, 1-10 nanogram genomic dna is used as template: primer, each 0.5 μ M (5 ' CATATCGACGACGACGACAAGCATATGCTCGAG[is in 5 ' 20 terminal aggressiveness ORF specificitys]; 5 ' ATCTTAAGCGTAATCCGGAACATCGTATGGGTA[is in 3 ' 20 terminal aggressiveness ORF specificitys]; 0.02U/ μ lTaq archaeal dna polymerase [Fisher Scientific, buffer A]; 0.1mg/ml [come from pig, Bloom 300 for gelatin; Sigma, G-1890]; 0.2mM every kind of dNTP; Initial sex change: 95 ℃, 5 minutes; 30 circulations: 95 ℃ following 20 seconds, 50 ℃ following 0.5 minute, 72 ℃ every 1kb1 minute down, based on the ORF size, average 1-3 minute; The final extension: 72 ℃ following 10 minutes).With (rather than 50 ℃) annealing under 45 and 40 ℃ 0.5 minute, the PCR product of the more difficult preparation of amplification again.Purifying (Qiagen PCR purification kit) PCR product is undertaken quantitatively by the fluorescence art with picogreen (MolecularProbes, Eugene OR), manifests to confirm size and purity by agarose gel electrophoresis.

[0109] with gene-specific primer from genomic templates each open reading-frame (ORF) that increases.5 ' oligonucleotide contains 53 Nucleotide; 33 Nucleotide wherein comprise 5 ' general end sequence, other 20 Nucleotide constitutive gene specific sequences.First initiator codon ATG is positioned at the upstream of the polyhistidine tag on the linear carrier, and each open reading-frame (ORF) also begins with ATG.3 ' customization oligonucleotide also contains 53 Nucleotide; Wherein form general end sequence for 33, other 20 nucleotide pairs are specificitys in interested gene.Add termination codon subsequence TTA at the end of gene order, with the translation termination of the gene realizing expressing.

[0110] primer is shown in Fig. 1, shows that the gel of the PCR product of one group of cleaning of drawing the amplification of hot Frances Salmonella from vaccinia virus and soil is shown in Fig. 2.For being shorter than 1, the gene of 000bp, the successful ratio of the PCR product that obtains predicting is greater than 99%.For these short genes,, can correct failure by adjusting new primer.Can increase 32 kind 1 000-2,28 kinds (81%) in the gene between the 000bp with the program that method partly describes in detail.Only can increase 8 kinds by these methods surpasses 2, in the gene of 000bp 3 kinds.Gene amplification that can these are longer is overlapping fragments, maybe can adopt the different PCR conditions of the longer product that helps increasing.

[0111] Embodiment 1A: these methods are applied to vaccinia virus, need the primer of 213 kinds of genes of preparation, wherein separated 211 kinds of PCR products (＞99%).Whole 211 kinds are cloned, 1 81 kinds in the product are checked order; 93% (in 181 kinds 169 kinds) provide the sequence of prediction.

[0112] Embodiment 1B: similarly, this method is applied to plasmodium falciparum, needs the primer of 720 kinds of genes of preparation.Obtain 462 kinds of PCR products (64%) thus, produced 266 clones (58%).To one group of (63) individual order-checking wherein, 97% has produced the sequence of expection.

[0113] Embodiment 1C: aforesaid method is used for mycobacterium tuberculosis, has prepared the primer of 108 kinds of genes for this reason.Obtained 87 kinds of PCR products (80%) thus, produced 80 clones (92%), wherein each all has anti-His mark at an end, has anti-HA mark at another end.Order-checking has confirmed that 70 (88%) among the clone of 79 tests contain the sequence of expection.In the albumen that great majority produce, His and HA mark may be used to combination, but under many circumstances, only in conjunction with a mark; Usually, when only can be in conjunction with a mark, the His mark keeps being used for combination, and HA epi-position mark can not be used for combination.

[0114] expanded this method, so that from the genome of 4,000 kinds of genomic constitutions of mycobacterium tuberculosis H37Rv, express 312 kinds of genes.

[0115] Embodiment 1D: aforesaid method is used for soil draws hot Frances Salmonella, prepared the primer of 1 933 kinds of genes for this reason.Obtain 1842 kinds of tight things of PCR (95%) thus, produced 1720 clones (93%).Wherein 684 are checked order, show that 643 (94%) contain the sequence of expection.

Embodiment 2

Reorganization and colony are selected in the body

[0116] mixture of the ORF of the pcr amplification of mix embodiment 1 and linear T7 carrier imports chemoreception attitude intestinal bacteria, obtains containing the colony with the conversion of inserting segmental plasmid.This efficient recombinant clone method has caused the interior direction of the frame of ORF to be inserted.

[0117] by under 18 ℃ at 500mlSOB substratum (2% tryptone, 0.5% yeast extract, 10mM NaCl, 2.5mM KCl and 20mM MgSO ₄) in growth DH5 α cell to the optical density(OD) of 0.5-0.7O.D., in our laboratory, prepare competent cell.Washed cell is resuspended in 10ml refrigerative PCKMS damping fluid (10mMPIPES, 15mM CaCl in advance on ice ₂, 250mM KCl, 55mM MnCl ₂With 5% sucrose, pH6.7), dropwise add 735 μ lDMSO under continuing to stir.On dry ice ethanol,, store down at-80 ℃ with freezing competent cells of branch thing such as 100 μ l.

[0118] the each conversion is grouped into by following one-tenth: (according to above preparing in our laboratory, efficient is 10 to 10 μ l competence DH5 α ⁹The supercoiled plasmid DNA of cfu/ μ g) and 10 μ lDNA mixtures (linear carrier that 40ng PCR-produces, the ORF fragment that 10ng PCR-produces; Mol ratio 1: 1, carrier: 1kb ORF fragment).With mixture incubation on ice 45 minutes; Heat shock (42 ℃, 1 minute) was cooled on ice 1 minute; With 250 μ lSOC substratum (2% tryptone, 0.55% yeast extract, 10mM NaCl, 10mM KCl, 10mMMgCl ₂, 10mM MgSO ₄, 20mM glucose) mix, 37 ℃ of following incubations 1 hour are diluted among the LB (Luria Bertani substratum) that 3ml added 50 μ g kantlex/ml (LB Kan 50), are incubated overnight under the vibration.Obtain single colony by being scoring on LB Kan 50 agar from overnight culture.From each conversion, select 2-3 colony further to analyze.By the plasmid DNA of gel electrophoresis observation, be used for selecting to have the segmental clone of insertion available from Qiagen miniprep.

[0119] be the conversion that the mixture of 1: 1 PCR fragment and linear carrier and total DNA that 50ng is used to transform finish DH5 α competent cell with mol ratio.The transformed competence colibacillus cell, grow overnight, and observing because the muddiness that bacterial growth causes, bed board and carry out colony and select then.Under these conditions, cloning efficiency＞90%, if but carry out bed board at conversion pair cell on the same day, observed success ratio is lower.Along with the total DNA that is used to transform reduces to 25 and 10ng, the ratio that success transforms reduces (not shown) gradually.

[0120] Fig. 3 has shown " disruptive gel " (phenol-chloroform cracked bacterium shows total nucleic acid) that obtains from overnight culture with PCR fragment shown in Figure 2.Top strap on these gels is a genomic dna, and two bands in bottom are heavy and light ribosome-RNA(rRNA)s, and the intermediary band is the plasmid by forming with linear carrier and the reorganization of PCR fragment.Comprised in this gel that empty carrier is as reference.In 87 plasmids shown in this figure, 3 insertion fragments that lack suitable size are only arranged.

[0121] with overnight culture shown in Figure 3 line on agar plate, select 2 colonies, grow and carry out micropreparation.The micropreparation thing that derives from the single colony of overnight culture is shown in Fig. 4.Plasmid to purifying checks order, and proves the fidelity of reproduction of recombinant products.According to the genomic sequence data storehouse major part being inserted fragment accurately checks order.74% does not have sudden change, and 20% has a single point sudden change, and 6% has an above point mutation.41% point mutation is A → G; Remaining sudden change stochastic distribution in the possible point mutation of other 11 class.

Embodiment 3

Proteic in-vitro transcription and translation detect

[0122] express encoded protein on the plasmid shown in Figure 4 in based on colibacillary acellular in-vitro transcription/translation system, described system has replenished t7 rna polymerase.With the plasmid of Qiagen micropreparation test kit preparation as the template of every kind of micropreparation thing of 0.5 μ g, and comprised " choosing wantonly " step, described step has comprised protein denaturant, to eliminate the RNA enzymic activity.If do not comprise this step, the expression level in in-vitro transcription/translation reaction will be low with inconsistent.In 0.2ml PCR 12 empty band pipes, set up in-vitro transcription/translation reaction (available from the RTS 100 intestinal bacteria HY test kits of Roche) with 25 μ l reaction volumes, according to the explanation of manufacturers, 30 ℃ of following incubations 5 hours.Carry out Western blot with mouse anti Histidine antibody with alkaline phosphatase link coupled goat anti-mouse antibody.

[0123] in order to obtain result shown in Figure 5, in in-vitro transcription/translation reaction, 50 different soil were drawn hot Frances Salmonella and vaccinia virus plasmid incubation 4 hours, product is carried out electrophoresis on sds page, gel is carried out trace and detection with anti-polyhistidyl antibody.Western blot among Fig. 5 has shown the expression of the product of the histidine mark with predicted molecular weight, has only 3 to be negative in 50 plasmids.

[0124] also can on Dot blot, detect not metaprotein (Fig. 6) from acellular reaction.The direct point sample of every kind of in-vitro transcription/translation reaction of 1 microlitre on nitrocellulose, and is not had the SDS sex change, survey Dot blot with anti-Histidine or anti-HA antibody.Show from 50 vaccinia virus clones and 45 reaction product (Fig. 6) that soil draws hot Frances Salmonella clone.When surveying Dot blot with anti-Histidine antibody, a vaccinia virus reaction and 3 soil draw hot Frances Salmonella not to be higher than background.When surveying Dot blot with anti-HA antibody, there is the more negative reaction of high number, supposition is to show this epi-position more frequent being hidden in the three-dimensional structure of metaprotein not, because electrophoresis and western blot analysis are not found the preceding protein product of competent maturation, this is because the premature termination in the translation process.(other details of preparation Dot blot is described in embodiment 4).

Embodiment 4

Microarray and serological screening

[0125] (Winnipeg, vaccinia virus immunoglobulin (Ig) (VIG) Canada) have been adopted available from Cangene Corp.VIG is the immunoglobulin fraction from the hyper-immuneserum of a plurality of donors merging.It is as the patient's who is experiencing hologathy toxicaemia that the vaccinia virus inoculation causes and other untoward reaction emergency treatment.

[0126] for the immunodotting trace, the full RTS of 0.3 μ l volume is reacted artificial point sample on nitrocellulose filter, dry, then with the sealing of 5% skim-milk among the TBS-Tween.Survey trace with VIG, in the sealing damping fluid that contains or do not contain 10% intestinal bacteria lysate, be diluted to 1/1,000.Three crowdes of different VIG have been adopted: lot number 1730204 (56mg/ml), lot number 1730208 (53mg/ml) and lot number 1730302 (56mg/ml).Detect people's antibody by incubation in the anti-people IgA+IgG+IgM of alkaline phosphatase link coupled goat (H+L) second antibody (JacksonImmunoResearch) and with nitro-BT photographic developer observation.Routinely, also use monoclonal anti polyhistidyl (clone His-1; Sigma H-1029) and mono-clonal rat anti hemagglutinin (clone 3F10; Roche 1867423) antibody, use AP link coupled goat anti-mouse IgG (H+L) (BioRad) or the mouse IgG of the goat Chinese People's Anti-Japanese Military and Political College (H+L) second antibody (Jackson ImmunoResearch) dyeing then respectively, to confirm existing of recombinant protein.

[0127] sets up in-vitro transcription/translation reaction with 25 μ l scales, also set up and adopted the control reaction of non-recombinant expression plasmid, so that the contrast that exists as bacillus coli antigen as template.After 5 hours building-up reactionss finish, immediately with the albumen point sample or be arranged on the nitrocellulose matrix, and be not further purified, or remain on and be no more than 12 hours under 4 ℃, then trace.Under non-sex change condition, carry out the point sample of RTS reaction, and be not further purified (Fig. 7).Find that colibacillary antibody all is high titre in human serum and VIG, unless and be closed, then cause covering the high background dyeing of any antigen-specific reaction.This is by to remove Chinese People's Anti-Japanese Military and Political College enterobacteria reactive or overcome with blocking antibody by introduce 10% intestinal bacteria lysate in serum or VIG with being fixed on e. coli protein on the nitrocellulose filter.In fact, our effect of finding to adsorb immunoblotting with block to compare and have nothing different (data not shown goes out) by adding lysate.Therefore, a kind of technology in back is used as the painted ordinary method of blocking-up intestinal bacteria background, and this is because it allows to use (typical case is each microarray 2-3 μ l) with the consistency of high flux screening and the economy of human serum.When introducing lysate, the intensity of spot significantly reduces in the control reaction, causes at the proteic stronger signal to noise ratio of antigenicity vaccinia virus.Should notice that also VIG is a conformation dependent to the reactivity of A11L.In Western blot, discern this specific antigen easily, but nonrecognition in the non-denatured form of Dot blot.

Embodiment 5

Microarray

[0128] Fig. 8 shows the flight microarray that adopts identical RTS reaction, and described RTS reaction is used for the immunodotting trace that Fig. 7 describes.For microarray, at first 15 μ l volumes are transferred in 384 orifice plates, 1,600xg is centrifugal, to be settled out all throw outs, under situation about not being further purified, use Omni Grid 100 microarray trace instrument (Gene Machines) with the FAST of supernatant liquor trace to nitrocellulose bag quilt ^TMSlide glass (Schleicher﹠amp; SchuellBioscience) on.For all dyeing, at first slide glass is sealed damping fluid (Schleicher﹠amp in protein arrays; Schuell) sealing is 1 hour in, uses first and second antibody identical with Dot blot (adopting the Cy3 link coupled second antibody available from Jackson) dyeing, scans in laser cofocal scanner.(GSI Lumonics Inc) carries out quantitatively fluorescence intensity with QuantArray software.When adopting full RTS to react on Dot blot and array, VIG has Chinese People's Anti-Japanese Military and Political College's enterobacteria antibody of any antigen-specific reaction of covering of high titre.This is to overcome by the immunoblotting that makes VIG absorption intestinal bacteria lysate or by the intestinal bacteria lysate is added VIG.In preceding a kind of method, intestinal bacteria are dissolved in the SDS PAGE sample buffer, on the preparation gel, differentiate lysate, transfer to Optitran nitrocellulose filter (Schleicher﹠amp then; Schuell) on.Then trace is cut into little (5 * 5mm) sheets, and in 5% skim-milk the sealing 1 hour.Wash described small pieces then, be placed in advance with the sealing damping fluid and be diluted among 1/1000 the VIG, continued to stir down incubation 1 hour.1 liter of intestinal bacteria (DH5) culture stationary phase from be resuspended in 25ml TBS-Tween prepares the intestinal bacteria lysate, with the probe sonication of 2cm diameter.Branch things such as 1ml are stored down at-80 ℃.

[0129] under the condition of purifying not with in-vitro transcription/translation reaction trace to the slide glass of nitrocellulose bag quilt, survey with the VIG that contains and do not contain 10% intestinal bacteria lysate.The contrast spot is formed as the RTS reaction of carrier by having non-recombinant expression plasmid.By calculating the mean value and the standard deviation of the fluorescence intensity that contrasts spot, set up " by value " (dyeing that is higher than it can be thought male) arbitrarily.As can be seen, when having lysate among the VIG, also detected detected same protein in the immunodotting trace by microarray.Fluorescence link coupled second antibody provides than using the observed strength of signal widely of immunodotting trace.As if in addition, microarray has also produced the sensitivity higher than immunodotting trace, because we have observed certain situation, wherein detected albumen is lower than the detection threshold (not shown) of Dot blot in array.

[0130] Fig. 9 has shown 96 vaccination seedling diseases poison and the native bigger array that draws hot Frances Salmonella albumen, adds a control reaction, and they are at PCR Express ^TMExpress on the platform.7 kinds of albumen of this array demonstration are discerned by force by VIG, and wherein 6 kinds is vaccinia virus albumen.In these albumen, 4 kinds (H3L, D8L, A56R and F13L) is the envelope antigen that can be touched by the lip-deep antibody of complete virion.Therefore, the proteic detection in this system has shown height antigen-specific and biology dependency.Unmodified form has extra advantage, and promptly albumen keeps their conformation dependent epi-position probably.

Embodiment 6

Prepare plasmid from transformation mixture

[0131] transformation mixture that will obtain according to the description of embodiment 2 is originated as the segmental plasmid of the insertion that contains needs, rather than selects single clone to be used for further assessment according to embodiment 2-5.As indicated above, the each conversion is grouped into by following one-tenth: 10 μ l competence DH5 α and 10 μ l DNA mixtures (linear carrier that 40ng PCR-produces, the ORF fragment from vaccinia virus that 10ng PCR-produces; Mol ratio 1: 1, carrier: 1kb ORF fragment).With mixture incubation on ice 45 minutes; Heat shock (42 ℃, 1 minute) was cooled on ice 1 minute; With 250 μ l SOC substratum (2% tryptone, 0.55% yeast extract, 10mM NaCl, 10mM KCl, 10mM MgCl ₂, 10mM MgSO ₄, 20mM glucose) mix, 37 ℃ of following incubations 1 hour are diluted among the LB (Luria Bertani substratum) that 3ml added 50 μ g kantlex/ml (LB Kan 50), are incubated overnight under the vibration.Separate and plasmid purification from this culture, do not select and do not carry out colony.Substantially translate the plasmid template that obtains according to the description of front embodiment, according to hereinafter transferring to the immunodotting trace.

[0132] prepare the plasmid template that is used for in-vitro transcription/translation with Qiagen micropreparation test kit, comprised " choosing wantonly " step, described step has comprised protein denaturant, to eliminate the RNA enzymic activity.If do not comprise this step, the expression level in in-vitro transcription/translation reaction will be low with inconsistent.Figure 10 uses the PCR fragment from vaccinia virus to show " disruptive gel " (phenol-chloroform cracked bacterium shows total nucleic acid) from overnight culture.Top strap on these gels (direction is towards the right side) is a genomic dna, and two bands in bottom are 23S and 16S ribosome-RNA(rRNA), and the intermediary band is the plasmid by forming with the reorganization of linear carrier and PCR fragment.Comprised in this gel that empty carrier is as reference.In 42 plasmids shown in this figure, only there be 1 (E9L) to lack the insertion fragment of suitable size.In order to calibrate the efficient of overall system, increased, cloned and expressed one group of test cdna that draws hot Frances Salmonella from soil.In 1,933 kind of gene attempting, 96% is successfully increased, and 93% is successfully cloned.

[0133] in 0.2ml PCR 12 empty band pipes, set up in-vitro transcription/translation reaction (available from the RTS 100 intestinal bacteria HY test kits of Roche) with 25 μ l reaction volumes, according to the explanation of manufacturers, 30 ℃ of following incubations 5 hours.Be expressed in one group of 8 vaccination of representative seedling diseases poison and 40 kinds of soil of encoding on the T7 plasmid and draw the proteic albumen of hot Frances Salmonella in based on colibacillary acellular in-vitro transcription/translation system, described system has replenished t7 rna polymerase.With 37 ℃ of following incubations of 25 μ l in-vitro transcription/translation reactions 4 hours, crude product is differentiated on sds page, with anti-polyhistidyl antibody gel is carried out trace and detection (Figure 11).Western blot has shown the expression of product of the histidine mark of predetermined molecular weight.A little less than 3 reactions too in 48 reactions, it is positive to mark.

[0134] for the immunodotting trace, the full RTS of 0.3 μ l volume is reacted artificial point sample on nitrocellulose filter, dry, then with the sealing of 5% skim-milk among the TBS-Tween.Be used in be diluted in the sealing damping fluid that contains or do not contain 10% intestinal bacteria lysate 1/1000 (Canada) vaccinia virus immunoglobulin (Ig) (VIG) is surveyed trace for Winnipeg, Manitoba available from Cangene Corporation.Three crowdes of different VIG have been adopted: lot number 1730204 (56mg/ml), lot number 1730208 (53mg/ml) and lot number 1730302 (56mg/ml).Detect people's antibody by incubation in the anti-people IgA+IgG+IgM of alkaline phosphatase link coupled goat (H+L) second antibody (Jackson ImmunoResearch) and with nitro-BT photographic developer observation.Routinely, also use monoclonal anti polyhistidyl (clone His-1; SigmaH-1029) and mono-clonal rat anti hemagglutinin (clone 3F10; Roche 1867423) antibody, use AP link coupled goat anti-mouse IgG (H+L) (BioRad) or the mouse IgG of the goat Chinese People's Anti-Japanese Military and Political College (H+L) second antibody (Jackson ImmunoResearch) dyeing then respectively, to confirm existing of recombinant protein.For microarray, the Tween 20 of 10 μ l0.125% is mixed (to obtain the final concentration of 0.05%Tween) with 15 μ l RTS reaction, 15 μ l volumes are transferred in 384 orifice plates.With plate 1,600xg is centrifugal, to be settled out all throw outs, uses Omni Grid 100 microarray trace instrument (Gene Machines) with the FAST of supernatant liquor trace to nitrocellulose bag quilt under situation about not being further purified ^TMSlide glass (Schleicher﹠amp; Schuell Bioscience) on.For all dyeing, at first slide glass is sealed damping fluid (Schleicher﹠amp in protein arrays; Schuell) sealing is 30 minutes in, uses first and second antibody identical with Dot blot (adopting the Cy3 link coupled second antibody available from Jackson) dyeing, scans in laser cofocal scanner.(GSI Lumonics Inc) carries out quantitatively fluorescence intensity with QuantArray software.When adopting full RTS to react on Dot blot and array, VIG has Chinese People's Anti-Japanese Military and Political College's enterobacteria antibody of any antigen-specific reaction of covering of high titre.This is to overcome by the immunoblotting that makes VIG absorption intestinal bacteria lysate or by the intestinal bacteria lysate is added VIG.In preceding a kind of method, intestinal bacteria are dissolved in the SDS PAGE sample buffer, on the preparation gel, differentiate lysate, transfer to Optitran nitrocellulose filter (Schleicher﹠amp then; Schuell) on.Then trace is cut into little (5 * 5mm) sheets, and in 5% skim-milk the sealing 1 hour.Wash described small pieces then, be placed in advance with the sealing damping fluid and be diluted among 1/1000 the VIG, continued to stir down incubation 1 hour.1 liter of intestinal bacteria (DH5) culture stationary phase from be resuspended in 25ml TBS-Tween prepares the intestinal bacteria lysate, with the probe sonication of 2cm diameter.Branch things such as 1ml are stored down at-80 ℃.Lacking the reactive mice serum of endogenous Chinese People's Anti-Japanese Military and Political College enterobacteria does not need to anticipate with intestinal bacteria and reduces background.

[0135] also can on the immunodotting trace, detect non-denatured protein (Figure 12) from not celliferous reaction.Vivoexpression 128 the coding 112 kinds of proteic plasmids of different vaccinia viruss, with each unpurified reaction double point sample of 1 microlitre on nitrocellulose filter.The open reading-frame (ORF) of every kind of gene is designed to comprise N-end 10 * Histidine (HIS) mark and C-terminal hemagglutinin mark (sequence YPYDVPDYA).Also set up the control reaction (' c ') that lacks plasmid template; If the use empty carrier owing to produced little 10 * Histidine positive fragment, has been observed positive signal (data not shown goes out).With anti-HIS traget antibody (Figure 12 A), anti-HA traget antibody (Figure 12 B), vaccinia virus immunoglobulin (Ig) (VIG) (Figure 12 C) or VIG+10% intestinal bacteria lysate (Figure 12 C) detection membrane.Anti-HIS and HA traget antibody do not have other proteic cross reaction in demonstration and the vitro reactions, the therefore conventional expression that is used to monitor big quantitative response.In 112 kinds of different albumen of expressing, only there are 3 kinds all to be negative to HIS (Figure 12 A) and HA (Figure 12 B) mark.In order to assess the overall efficiency of expression, the soil of having expressed 390 kinds of clones draws hot Frances Salmonella gene, will react point sample to nitrocellulose filter, surveys with anti-Histidine or anti-HA antibody.82% reaction is the HA male, and 84% is 10 * polyhistidyl male, the 73%th, and Histidine and HA male, the 7%th, HA and Histidine feminine gender.

[0136] from the trace of Figure 12 C as can be seen, VIG has Chinese People's Anti-Japanese Military and Political College's enterobacteria antibody of high titre, has covered and proteic all reactivities of vaccinia virus.But, in VIG, add intestinal bacteria lysates (Figure 12 D), this background is reduced to can detect the proteic level of vaccinia virus.Positive protein on this trace is A10L, A27L, and D8L, D13L, F13L, H3L and H5R emphasize with redness in title.

[0137] handles serum with the intestinal bacteria lysate and also can effectively reduce intestinal bacteria background response on the microarray.23 vaccination seedling diseases poison and 22 kinds of soil of surveying with the VIG that contains and do not contain the intestinal bacteria lysate draw the flight microarray of hot Frances Salmonella albumen composition to be shown in Figure 13.The effect (shown in the Dot blot of Figure 12 C) of Chinese People's Anti-Japanese Military and Political College's enterobacteria antibody of high titre also is tangible (Figure 13, top array) on microarray.The high background that also exists in the contrast prepared product has been covered the proteic specific reaction of vaccinia virus.Before surveying microarray, add 10% intestinal bacteria lysate, reduced the intestinal bacteria background, shown specific reaction (Figure 13, figure below).This array has shown 5 vaccination seedling diseases toxalbumin by VIG (adding frame), D13L, and D8L, F13L, H3L and H5L discern by force.

[0138] Figure 14 has shown the result of the array of forming from 194 kinds of albumen of the complete vaccinia virus gene group of estimating representative＞95%.Personnel selection vaccinia virus immunoglobulin (Ig) (VIG), and the vaccinia virus inoculation of using by oneself is preceding and this array of serum screening of postvaccinal mouse and macaque.Figure 14 A has shown that not contacted antigenic not immune mouse lacks all proteic reactivities that list poised for battle fully, but the antigen-reactive of a subgroup on serum of the mouse that immunity is crossed from vaccinia virus and the array.Different with not contacted antigenic mouse, the antigen-reactive of a subgroup on non-immune people and the array, but with after the vaccinia virus immunity, with the antigen-reactive of another subgroup on the array.The last figure that quantitatively is illustrated in Figure 14 B of data.VIG discerns 26 kinds of different albumen, wherein by also having observed 13 kinds from the serum of the individuality of contacted vaccinia virus not, therefore thinks and represents the non-specific cross-reaction of antibody to other environmental antigens.Remaining 13 kinds is the antigen of the antibodies specific identification that produces in the vaccinia virus immunologic process.In serum, also observed similar collection of illustrative plates (Figure 14 B) from macaque and mouse.Although existence specific specificity is replied (for example, only being A3L or A4L) in mouse, also exist much by the albumen of people and any animal model corecognition with by 10 kinds of albumen (table 1) of all three species identification.These specific antigens will be the preferential material standed fors that is used for the clinical Pretesting of human vaccine.Generally, be the major portion of replying to replying of virus structural protein, described proteic over half all be envelope protein (table 1).Seropositivity albumen comprises having and do not have membrane spaning domain and PI is the albumen of 4-10, and described structural domain has and do not have signal peptide.In addition, reported in the past that some described albumen produced humoral response in animal and human's class, other albumen does not then produce.

[0139] antigen in the table 1 all is the antigen that keeps (WR) strain from the west, but identifies to the title of homologue by them and the nearest straight of vaccinia virus Copenhagen strain herein, because the sign of protein function in this strain is better.Yet, can obtain from the GenBank database from each ORF of WR strain and the sequence of encoded protein, this database can be inquired about from network, and network address is Www.ncbi.nlm.nih.gov/gquery/gquery.fcgiExplanation in the table 1 and the explanation in the database are complementary.The albumen of WR strain and gene order are arranged in vaccinia virus WR genome, can find in GenBank with the gene title of table 1.The blast purposes that employing can obtain by GenBank can easily be identified and above-mentioned sequence and the similar substantially albumen of their corresponding gene sequences.

Table 1

Immunoreactive protein by this serological screening evaluation

The gene title	Antigen	PI	Molecular weight	Explanation	TM structural domain/signal peptide
						In mice immunized, people and macaque, has reactivity
VACWR129	A10L	6.33	102,283	Main core protein	Not/not
						VACWR130	A11R	4.81	36,134	Putative protein	Be/not
VACWR132	A13L	9.96	7,696	Structural protein	Be/be
						VACWR156	A33R	5.3	20,506	EEV glycoprotein	Be/be
VACWR181	A56R	4.05	34,778	Hemagglutinin	Be/be
						VACWR187	B5R	4.54	35,108	Patch size/host range albumen	Be/be
VACWR113	D8L	9.55	35,326	Cell surface-conjugated protein	Be/not
						VACWR118	D13L	5.10	61,890	Rifampicin resistance albumen	Not/not
VACWR052	F13L	6.98	41,823	Main envelope protein	Not/not
						VACWR101	H3L	6.43	37,458	The IMV membranin	Be/not
VACWR103	H5R	7.55	22,270	The late transcription factor	Not/not
						In the people of immunity and macaque, has reactivity
VACWR146/ 149 *	A26L	9.40	37,319	A type inclusion body albumen	Not/not

The gene title	Antigen	PI	Molecular weight	Explanation	TM structural domain/signal peptide
						In the people of immunity and mouse, has reactivity
VACWR150	A27L	5.14	12,616	Cytogamy albumen	Not/not
						VACWR059	E3L	5.04	21,504	The IFN resistance protein	Not/not
VACWR091	L4R	6.13	28,460	DNA syncaryon heart protein	Not/not
						In mice immunized and macaque, has reactivity
VACWR105	H7R	7.27	16,912	Putative protein	Not/not
						Only in the macaque of immunity, has reactivity
VACWR137	A17L	4.28	22,999	The IMV membranin	Be/be
						Only in mice immunized, has reactivity
VACWR122	A3L	6.75	72,624	Main core protein	Not/not
						VACWR123	A4L	4.68	30,846	Film associated core albumen	Not/not
VACWR116	D11L	9.13	72,366	The DNA helicase	Not/not
						VACWR104	H6R	10.30	36,665	Topoisomerase	Not/not
VACWR033	K2L	9.73	42,299	Serpin	Deny/be
						VACWR028	N1L	4.41	13,961	Putative protein	Not/not
Has reactivity at not contacted antigen (non-immune) philtrum
						VACWR166	A41L	4.90	25,092	Excretory glycoprotein	Deny/be
VACWR173	A47L	10.29	28,334	Putative protein	Not/not
						VACWR184	B2R	6.84	24,628	Putative protein	Not/not
VACWR115	D10R	8.12	28,934	The NTP phosphohydrolase	Deny/be
						VACWR057	E1L	8.71	55,580	Polyadenylate polymerase (VP55)	Not/not
VACWR041	F2L	8.64	16,264	The dUTP Pyrophosphate phosphohydrolase	Not/not
						VACWR048	F9L	6.72	23,792	The Trx substrate	Be/be
VACWR082	G5R	4.93	49,872	Core/assembling albumen	Not/not
						VACWR085	G7L	7.72	41,920	Structure/core protein	Not/not
VACWR105	H7R	7.27	16,912	Putative protein	Not/not
						VACWR070	I1L	9.05	35,841	Telomere binding protein	Not/not
VACWR092	L5R	10.32	15,044	Myristoylation albumen	Be/not
						VACWR069	O2L	5.27	12,355	Glutaredoxin	Not/not

The gene title	Antigen	PI	Molecular weight	Explanation	TM structural domain/signal peptide
						In mice immunized, people and macaque, has reactivity
VACWR129	A10L	6.33	102,283	Main core protein	Not/not
						VACWR130	A11R	4.81	36,134	Putative protein	Be/not
VACWR132	A13L	9.96	7,696	Structural protein	Be/be
						VACWR156	A33R	5.3	20,506	EEV glycoprotein	Be/be
VACWR181	A56R	4.05	34,778	Hemagglutinin	Be/be
						VACWR113	D8L	9.55	35,326	Cell surface-conjugated protein	Be/not
VACWR118	D13L	5.10	61,890	Rifampicin resistance albumen	Not/not
						VACWR052	F13L	6.98	41,823	Main envelope protein	Not/not
VACWR101	H3L	6.43	37,458	The IMV membranin	Be/not
						VACWR103	H5R	7.55	22,270	The late transcription factor	Not/not
In the people of immunity and macaque, has reactivity
						VACWR146/149 *	A26L	9.40	37,319	A type inclusion body albumen	Not/not
In the people of immunity and mouse, has reactivity
						VACWR150	A27L	5.14	12,616	Cytogamy albumen	Not/not
VACWR091	L4R	6.13	28,460	DNA syncaryon heart protein	Not/not
						In mice immunized and macaque, has reactivity
VACWR187	B5R	4.54	35,108	Patch size/host range albumen	Be/be
						VACWR105	H7R	7.27	16,912	Putative protein	Not/not
Only in the macaque of immunity, has reactivity
						VACWR137	A17L	4.28	22,999	The IMV membranin	Be/be
Only in mice immunized, has reactivity
						VACWR122	A3L	6.75	72,624	Main core protein	Not/not
VACWR123	A4L	4.68	30,846	Film associated core albumen	Not/not
						VACWR116	D11L	9.13	72,366	The DNA helicase	Not/not
VACWR059	E3L	5.04	21,504	Adenosine deaminase	Not/not
						VACWR104	H6R	10.30	36,665	Topoisomerase	Not/not
VACWR033	K2L	9.73	42,299	Serpin	Deny/be
						VACWR028	N1L	4.41	13,961	Putative protein	Not/not

The gene title	Antigen	PI	Molecular weight	Explanation	TM structural domain/signal peptide
						Has reactivity at not contacted antigen (non-immune) philtrum
VACWR166	A41L	4.90	25,092	Putative protein	Deny/be
						VACWR173	A47L	10.29	28,334	Putative protein	Not/not
VACWR184	B2R	6.84	24,628	Putative protein	Not/not
						VACWR115	D10R	8.12	28,934	MutT sample albumen	Deny/be
VACWR057	E1L	8.71	55,580	Polyadenylate polymerase (VP55)	Not/not
						VACWR041	F2L	8.64	16,264	The dUTP Pyrophosphate phosphohydrolase	Not/not
VACWR048	F9L	6.72	23,792	The membranin of inferring	Be/be
						VACWR082	G5R	4.93	49,872	Putative protein	Not/not
VACWR085	G7L	7.72	41,920	The core protein of inferring	Not/not
						VACWR105	H7R	7.27	16,912	Putative protein	Not/not
VACWR070	I1L	9.05	35,841	The DNA that infers is conjugated protein	Not/not
						VACWR092	L5R	10.32	15,044	The membranin of inferring	Be/not
VACWR069	O2L	5.27	12,355	Glutaredoxin	Not/not

^*A26L albumen comprises VACWR146 and VACWR149.

[0140] induce the albumen that reacts with the very strong seropositivity of VIG to comprise A14L, A27L, H5R, D8R, D13L, D8L, H3L and F13L.These have medium immunoreactive Identification of Fusion Protein is A10L, A11R, LlR, B5R, A17L, I15L, F5L, A34L, A36R, A56R and A13L.Also identified the albumen of the very strong seropositivity reaction of another kind of generation and VIG; It is also referred to as VACWR148, and in the strain of Copenhagen, do not have close directly to homologue, but with smallpox in the albumen homology that is called A29L.It is antigenic not having in the past this Identification of Fusion Protein, and is called ATI locus albumen herein.

[0141] only be for example, rather than limit the albumen that the present invention includes or the scope of dna sequence dna, nearest directly the comprising of some immunoreactive proteins that the present invention identifies to homologue:

[0142] VACWR101 (VACV-COP H3L) other directly to homologue:

VACV-MVA：MVA093L

RPXV-UTR：RPXV-UTR_090

VACV-AMVA：AMVA095

CPXV-GRI：J3L

VACV-TAN：Tan-TH3L

VARV-GAR：J3L

VARV-BSH：I3L

VARV-IND：I3L

CMLV-CMS：98L

[0143] VACWR118 (VACV-COP D13L) other directly to homologue:

VACV-MVA：MVA 110L

VACV-TAN：an-TD15L

VACV-AMVA：AMVA112

CPXV-GRI：E13L

RPXV-UTR：RPXV-UTR_107

VARV-BSH：N3L

VARV-IND：N3L

CMLV-CMS：115L

CMLV-M96：CMLV116

[0144] VACWR 113 (VACV-COP D8L) other directly to homologue:

RPXV-UTR：RPXV-UTR_102

VACV-MVA：MVA105L

VACV-AMVA：AMVA107

VACV-TAN：Tan-TD8L

VARV-IND：F8L

VARV-BSH：F8L

VARV-GAR：F8L

ECTV-NAV：EV-N-114

ECTV-MOS：EVM097

[0145] VACWR052 (VACV-COP F13L) other directly to homologue:

VACV-TAN：an-TF13L

ECTV-NAV：EV-N-53

ECTV-MOS：EVM036

CPXV-GRI：G13L

RPXV-UTR：RPXV-UTR_041

VACV-AMVA：AMVA045

VACV-MVA：MVA043L

CPXV-BR：V061

VARV-GAR：E13L

[0146] VACWR103 (VACV-COP H5R) other directly to homologue:

RPXV-UTR：RPXV-UTR_092

VACV-TAN：Tan-TH6R

VACV-AMVA：AMVA097

VACV-MVA：MVA095R

CPXV-GRI：J5R

MPXV-ZRE：H5R

VARV-BSH：I5R

CPXV-BR：V114

VARV-GAR：J5R

[0147] VACWR187 (VACV-COP B5R) other directly to homologue:

RPXV-UTR：RPXV-UTR_167

VACV-TAN：Tan-TB5R

VACV-MVA：MVA173R

VACV-AMVA：AMVA173

CPXV-GRI：B4R

MPXV-ZRE：B6R

ECTV-MOS：EVM155

ECTV-NAV：EV-N-182

VARV-GAR：H7R

[0148] VACWR149+VACWR146 (VACV-COP A26L) other directly to homologue:

RPXV-UTR：RPXV-UTR_134

VACV-MVA：MVA137L

VACV-AMVA：AMVA139

CPXV-GRI：A27L

VACV-TAN：an-TA35L

MPXV-ZRE：A28L

CMLV-M96：CMLV145

CMLV-CMS：143L

CPXV-BR：V161

[0149] VACWR129 (VACV-COP A10L) other directly to homologue:

VACV-MVA：MVA121L

VACV-AMVA：AMVA123

RPXV-UTR：RPXV-UTR_118

CPXV-GRI：A11L

VACV-TAN：an-TA11L

CMLV-M96：CMLV127

CMLV-CMS：126L

VARV-GAR：A11L

VARV-BSH：A11L

[0150] VACWR130 (VACV-COP A11R) other directly to homologue:

VACV-AMVA：AMVA124

VACV-MVA：MVA122R

CPXV-BR：V143

CPXV-GRI：A12R

MPXV-ZRE：A12R

RPXV-UTR：RPXV-UTR_119

VACV-TAN：an-TA12R

ECTV-NAV：EV-N-131

ECTV-MOS：EVM114

[0151] VACWR181 (VACV-COP A56R) other directly to homologue:

VACV-AMVA：AMVA 167

VACV-MVA：MVA165R

VACV-TAN：an-TA66R

CPXV-GRI：A58R

MPXV-ZRE：B2R

CMLV-CMS：173R

VARV-GAR：K9R

CMLV-M96：CMLV176

VARV-BSH：J7R

[0152] VACWR091 (VACV-COP L4R) other directly to homologue:

VACV-MVA：MVA083R

RPXV-UTR：RPXV-UTR_080

VACV-AMVA：AMVA085

CPXV-BR：V102

CPXV-GRI：N4R

VACV-TAN：Tan-TL4R

VARV-IND：M4R

CMLV-M96：CMLV089

VARV-BSH：M4R

CMLV-CMS：88R

[0153] VACWR156 (VACV-COP A33R) other directly to homologue:

RPXV-UTR：RPXV-UTR_141

CPXV-GRI：A34R

VACV-TAN：R(TA43R)

VACV-MVA：MVA144R

VACV-AMVA：AMVA146

CMLV-M96：CMLV152

CMLV-CMS：150R

CPXV-BR：V168

MPXV-ZRE：A35R

[0154] be used to describe these directly to the abbreviation of homologue:

Copenhagen strain of VACV-Cop=vaccinia virus

The improved viral ankra of VACV MVA=vaccinia virus strain

VACV-AMVA=vaccinia virus Acambis 3000MVA strain

VACVWR=vaccinia virus west keeps strain

VACV-TAN=vaccinia virus Tian Tan strain

CPXV-GRI=cowpox GRI-90 strain

RPV-UTR=rabbitpox virus Utrecht strain

VARV-GAR=milk-pox virus Garcia strain

The strain of the big variola virus of VARV-BSH=Bangladesh

The strain of the big variola virus of VARV-IND=India

CMLV-CMS=camelpox virus CMS strain

CMLV-M96=camelpox virus M96 strain

ECTV-NAV=lacks the Naval strain (not delivering) of acropathy poison

ECTV-MOS=lacks the Moscow strain of acropathy poison

CPXV-BR=vaccinia virus Brighton Red strain

MPXV-ZRE=monkey pox virus Zaire-96-I-16 strain

[0155] based on mentioned above, suitable immune composition comprises to be selected from and is accredited as the proteic at least three kinds of albumen of antigenic one group of vaccinia virus herein, and this group comprises ATI locus albumen, A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L, H5R, A26L, A27L, E3L, L4R, H7R, A17L, A3L, A4L, D11L, H6R, K2L, NIL, A41L, A47L, B2R, D10R, E1L, F2L, F9L, G5R, G7L, H7R, I1L, L5R and O2L.Second kind of immune composition of the present invention comprises and is selected from activated proteic at least three kinds of albumen in the mammalian species of the immunity of at least a detection, and described albumen comprises ATI locus albumen, A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L, H5R, A26L, A27L, E3L, L4R, H7R, A17L, A3L, A4L, D11L, H6R, K2L and N1L.The third immune composition of the present invention comprises and is selected from one group has active proteic at least three kinds of albumen in the people of immunity, and this group comprises A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L, H5R, A26L, A27L, E3L and L4R.

[0156] other immune composition in the scope of the invention comprises at least three kinds and has reactive albumen by method discovery of the present invention in people, mouse and the macaque (all three species) of immunity, this group comprises A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L and H5R.Another kind of immune composition in the scope of the invention comprises and is selected from one group of antigenic at least a albumen of the most as one man being discerned by the individuality of panimmunity, and this group comprises ATI locus albumen, A10L, A13L, H3L, D13L, A11R and A17R.Based on the intensity of replying and conforming general impression, albumen type and similar consideration, another kind of preferred immune composition in the scope of the invention comprises at least two kinds, or more preferably at least three kinds of following vaccinia virus albumen: ATI locus, A10L, A13L, A26L, A56R, D8L, D13L, F13L, H5R and H3L.

[0157] preferred composition in the scope of the invention comprises and is selected from ATI locus albumen, A10L, at least two kinds of albumen of D13L and H3L.Other preferred immune composition comprises the A10L that is selected from the combination of other vaccinia virus antigen, D13L, and H3L and ATI locus be proteic as one man to have one of the basic homologous form of immunocompetent albumen or peptide or its or immunocompetence fragment.Therefore, for example, particularly preferred combination will comprise has made up H3L (or its basic homologue or immunocompetence fragment) and proteic those combinations of other immunogenicity vaccinia virus.Another kind of described combination comprises by ATI locus encoded protein or its basic homologue or immunocompetence fragment and other immunogenicity vaccinia virus albumen.Another embodiment comprises and being selected from a group and comprising A11R, A23L, at least a albumen of the neoantigen of A56R and H5R of at least a other antigenicity vaccinia virus protein combination.

[0158] for aforementioned each vaccine composition, the present invention also comprises corresponding D NA vaccine.Therefore, for every histone described herein, comprise one group of vaccine composition corresponding to the proteic gene of appointment and be also contained in the scope of the present invention, the respective combination of described gene and corresponding vaccinia virus antigenic protein gene is also contained in the scope of the present invention.

[0159] therefore, this method has been identified new immunoreactivity antigen, and not all these antigens can both be identified by the Forecasting Methodology of routine.The data that obtain with array are consistent with the immunoblotting of report before us, referring to Crotty, and S., et al, J.Immunol. (2003) 171:4969-4973 is incorporated herein by reference in full at this.Significantly, in the people of inoculation, we have found to strengthen for many years the back hypermnesia second of the dominant antigen of a subgroup have been replied behind initial immunity, be to H3L significantly, and D13L and A10L are proteic to be replied.

Embodiment 7

Transform culture with separating from single colony/clone or separating oneself The plasmid of mixture is protein expression relatively

[0160] having selected 28 kinds, to draw the size of hot Frances Salmonella from soil be the target gene of 300bp-2000bp, according to mentioned above, increase by PCR, adopt in the amplification and contain the primer that is connected sequence with the associated end homologous 20bp gene specific sequence and the 30bp of linear pIX expression vector (giving T7 promotor and N-terminal polyhistidyl syzygy).

[0161] the linear pIX prepared product with 25ng PCR product and same amount is pre-mixed.The DNA mixture is transformed in the 50 μ l chemoreception attitude e.colidh5s, placed 30 minutes on ice, 45 ℃ of following heat shocks 45 seconds mix with 500 μ l SOC substratum, then 37 ℃ of following incubations.After 1 hour, add the LB substratum that 500 μ l contain kantlex (50 μ g/ml), the following 37 ℃ of continuous incubations that vibrate then were greater than 14-24 hour.

[0162], subsequently 50 μ l culture bed boards is selected on the LB agar plate of (25 μ g/ml) under 37 ℃ incubation 12-14 hour once more having kantlex for single clone's program.Select single colony then, spend the night, carry out DNA with Qiagen micropreparation test kit then and separate with the same medium subculture.

[0163] or, the direct isolated plasmid dna of the transformation mixture that spends the night from the first step above.

[0164] will add that 20 μ l Roche RTS100 are not celliferous to transcribe/translate mixture from the plasmid DNA (5 μ l) of step 2 and 3,30 ℃ of following incubations 4 hours.0.5 μ l is expressed the mixture point sample on nitrocellulose filter, with anti-polyhistidine tag monoclonal antibody expressed proteins is carried out the standard protein trace then and detect.

Table 2

Protein expression from single clone and transformation mixture

(result who shows difference between two kinds of methods emphasizes with redness)

[0165] single clone: 18 samples in 28 samples have shown target gene expression.But 10 samples do not produce the protein expression of any detection level.

[0166] transformation mixture: 23 samples in 28 samples have shown expression.Shown expression from 5 in 10 negative samples of single clone's scheme, shown that the plasmid from single colony may contain the sudden change that prevents that encoded protein from expressing.

Embodiment 8

The H3L epitope scanning

[0167] vaccinia virus envelope protein H3L is divided into 10 overlapping fragmentses of being made up of 50 amino acid, as shown in figure 15.For each fragment, designed forward and reverse primer that length is 53bp, as shown in table 3.When in the linearizing of BamH1 site, primer sequence comprise with the DNA of the terminal complementary 33bp of pXi (source) carrier and with the DNA of specific fragment end complementary 20bp.

[0168] for each fragment of pcr amplification, it is 50ul that vaccinia virus gene group DNA and 10 μ M specificity forwards and reverse primer, water and Eppendorf HotMaster are mixed into final volume.For 30 circulations, sex change was carried out under 94 ℃ 30 seconds, annealed 30 seconds down at 50 ℃ then, extended 30 seconds down at 68 ℃.Behind the PCR, on 1% agarose, product is carried out electrophoresis, with the success of assessment amplification.Gel shows enough products of fragment 1,2 and 6, and the gel of scanning shows that 3,4,8 and 10, the three enough gels show enough 9.The PCR reaction does not all have successful amplified fragments 5 and 7.Therefore, increase 7 respectively with 4 and 6 forward and reverse primer amplification 5 (rather than fragments of these two 150bp that increase), and with 6 and 8 forward and reverse primer.The amplification of these 450bp sequences is successful.

[0169] carry out pcr amplification and cleaning PCR product with Qiagen PCR purification kit after, with recombinant clone method cloned sequence.The PCR product of the linearizing pXi carrier of 40ng with the 10ng cleaning mixed, in this mixture, add 10ul DH5 α competent escherichia coli cell.Then mixture was placed on 45 minutes on ice, 42 ℃ of following heat shocks 1 minute are returned then and were placed on ice 1 minute again.Remove mixture, in each test tube, add 200ul SOC substratum, with mixture incubation 1 hour in 37 ℃ of water-baths.Transformation mixture is mixed with 3mL LB+ kantlex, under 37 ℃, be incubated overnight.

[0170] use the micropreparation test kit from the transformation mixture isolated plasmid dna.Carry out gel electrophoresis, to determine whether plasmid has insertion sequence.In contrast, annular pXi carrier is carried out electrophoresis.The result shows that design contains fragment 1,2, and 3,6,8,9 and 10 plasmid has insertion sequence.

Table 3

The H3L primer

Primer sequence

Fragment dna sequence dna FP (5 '-3 ') RP (5 '-3 ')

ATGGCGGCGGCGAAAACTCC CATATCGAC ATCTTAAGCG

TGTTATTGTTGTGCCAGTTAT GACGACGAC TAATCCGGA

TGATAGACTTCCATCAGAAAC AAGCATATG ACATCGTATG

ATTTCCTAATGTTCATGAGCA CTCGAGATG GGTAGCACA

(1)TATTAATGATCAGAAGTTCGA GCGGCGGCG ACATTTCTTT

TGATGTAAAGGACAACGAAG AAAACTCC TTTCTG

TTATGCCAGAAAAAAGAAAT

GTTGTG

Primer sequence

Fragment dna sequence dna FP (5 '-3 ') RP (5 '-3 ')

GATCAGAAGTTCGATGATGT CATATCGAC ATCTTAAGCG

AAAGGACAACGAAGTTATGC GACGACGAC TAATCCGGA

CAGAAAAAAGAAATGTTGTG AAGCATATG ACATCGTATG

GTAGTCAAGGATGATCCAGA CTCGAGGAT GGTAGGTGA

(2)TCATTACAAGGATTATGCGTT CAGAAGTC GTATACTTGT

TATACAGTGGACTGGAGGAA GATGATGT CATCAT

ACATTAGAAATGATGACAAGT

ATACTCAC

GATTATGCGTTATACAGTGG CATATCGAC ATCTAAGCG

ACTGGAGGAAACATTAGAAA GACGACGAC TAATCCGGA

TGATGACAAGTATACTCACTT AAGCATATG ACATCGTATG

CTTTTCAGGGTTTTGTAACAC CTCGAGGAT GGTAGAAAA

(3)TATGTGTACAGAGGAAACGA TATGCGTTTA AAATTAGAAT

AAAGAAATATCGCTAGACATT TACAGTG CCCATA

TAGCCCTATGGGATTCTAATT

TTTTT

ACAGAGGAAACGAAAAGAAA CATATCGAC ATCTTAAGCG

TATCGCTAGACATTTAGCCCT GACGACGAC TAATCCGGA

ATGGGATTCTAATTTTTTTAC AAGCATATG ACATCGTATG

CGAGTTAGAAAATAAAAAGG CTCGAGACA GGTAGCAAG

(4)TAGAATATGTAGTTATTGTAG GAGGAAACG ACGGGACGA

AAAACGATAACGTTATTGAG AAAAGAAA AGAAACG

GATATTACGTTTCTTCGTCCC

GTCTTG

GTAGTTATTGTAGAAAACGAT CATATCGAC ATCTTAAGCG

AACGTTATTGAGGATATTACG GACGACGAC TAATCCGGA

TTTCTTCGTCCCGTCTTGAAG AAGCATATG ACATCGTATG

GCAATGCATGACAAAAAAAT CTCGAGGTA GGTAGTTTGT

(5)AGATATCCTACAGATGAGAG GTTATTGTA CCATTACAAG

AAATTATTACAGGCAATAAAG GAAAACGA CTCGG

TTAAAACCGAGCTTGTAATGG

ACAAA

Primer sequence

Fragment dna sequence dna FP (5 '-3 ') RP (5 '-3 ')

CTACAGATGAGAGAAATTATT CATATCGAC ATCTTAAGCG

ACAGGCAATAAAGTTAAAAC GACGACGAC TAATCCGGA

CGAGCTTGTAATGGACAAAA AAGCATATG ACATCGTATG

ATCATGCCATATTCACATATA CTCGAGCTA GGTAGATCT

(6)CAGGAGGGTATGATGTTAGC CAGATGAGA ACGATGTTCA

TTATCAGCCTATATTATTAGA GAAATTAT GCGCCG

GTTACTACGGCGCTGAACAT

CGTAGAT

TATGATGTTAGCTTATCAGCC CATATCGAC ATCTTAAGCG

TATATTATTAGAGTTACTACG GACGACGAC TAATCCGGA

GCGCTGAACATCGTAGATGA AAGCATATG ACATCGTATG

AATTATAAAGTCTGGAGGTCT CTCGAGTAT GGTAGCAGT

(7)ATCATCGGGATTTTATTTTGA GATGTTAGC ATCTGCCTAT

AATAGCCAGAATTGAAAACG TTATCAGC TGATCT

AAATGAAGATCAATAGGCAG

ATACTG

GGATTTTATTTTGAAATAGCC CATATCGAC ATCTTAAGCG

AGAATTGAAAACGAAATGAA GACGACGAC TAATCCGGA

GATCAATAGGCAGATACTGG AAGCATATG ACATCGTATG

ATAATGCCGCCAAATATGTAG CTCGAGGGA GGTAGTATTC

(8)AACACGATCCCCGACTTGTTG TTTTATTTTG TAGACCAAA

CAGAACACCGTTTCGAAAAC AAATAGC AATTCG

ATGAAACCGAATTTTTGGTCT

AGAATA

CCCCGACTTGTTGCAGAACA CATATCGAC ATCTTAAGCG

CCGTTTCGAAAACATGAAACC GACGACGAC TAATCCGGA

GAATTTTTGGTCTAGAATAGG AAGCATATG ACATCGTATG

AACGGCAGCTACTAAACGTT CTCGAGCCC GGTAGAACA

(9)ATCCAGGAGTTATGTACGCG CGACTTGTT TTAATATCAA

TTTACTACTCCACTGATTTCA GCAGAACA ACAATC

TTTTTTGGATTGTTTGATATT

AATGTT

Primer sequence

Fragment dna sequence dna FP (5 '-3 ') RP (5 '-3 ')

GTTATGTACGCGTTTACTACT CATATCGAC ATCTTAAGCG

CCACTGATTTCATTTTTTGGA GACGACGAC TAATCCGGA

TTGTTTGATATTAATGTTATA AAGCATATG ACATCGTATG

(10)GGTTTGATTGTAATTTFGTTT CTCGAGGTT GGTAGTTAG

ATTATGTTTATGCTCATCTTT ATGTACGCG ATAAATGCG

AACGTTAAATCTAAACTGTTA TTTACTAC GTAACGA

TGGTTCCTTACAGGAACATTC

GTTACCGCATTTATCTAA

Embodiment 9

With the Protein Detection t cell activation that is fixed on the pearl

[0171] adopt method mentioned above, basic all protein groups of the biology of considering with T7 carrier (pTX7) clone (as vaccinia virus), and with acellular vitro system expressing protein.The adapter that is used for every kind of albumen is inserted carrier comprises polyhistidine tag, so expressed proteins can be captured on the pearl of the nickel bag quilt of using sample loading buffer (the 10mM imidazoles, pH 8.0 for 300mM NaCl, 50mM sodium phosphate) equilibrated 1 μ m in advance.The pearl of nickel bag quilt can be any size, but advantageously less than the APC cell, the typical case is the about 10-20 micron of diameter; Can obtain the pearl of the nickel bag quilt of 1-3 micron size, and be enough to be used in this purpose.Then in lavation buffer solution (except the imidazoles that contains is the 20mM, with above the same) with the pearl of albumen bag quilt washing 5 times, washed twice in tissue culture medium (TCM) is resuspended in then in the substratum of serum-free and arrives 12.5 initial μ l volumes.These pearls with the antigen presenting cell incubation, are mixed with 96 hole mensuration forms with the T cell then.

[0172] from pathogenic agent (as intraperitoneal give 2 * 10 ⁵The pfu vaccinia virus) subcutaneous each recombinant protein mice immunized that gives of intraperitoneal or tail basis pontis obtains or in adjuvant, or obtains to reply the T cell from people's donor of infected/immunity.Under the situation of mouse, the immunity back was taken out spleen or draining lymph node in 7-10 days.Then antigen coated pearl (normally every hole 1-5 μ l) is added mice spleen cell or human peripheral blood mononuclear cell (PBMC in Multiscreen 96 orifice plates (Millipore MAHAS45) of using anti-mouse or people IFN-γ (from Pharmingen) bag quilt in advance; 5 * 10 ⁵Cells/well), in the tissue culture medium (TCM) that contains 10% foetal calf serum (FCS) (mouse mensuration) or 5% people AB serum (people's mensuration), sealed 1 hour.For example, can will resist mouse or people IFN-γ to be fixed in the hole on the nitrocellulose matrix; In the case, handle the site that does not occupy that to seal on the Mierocrystalline cellulose, otherwise described site can in conjunction with capture antibody and interference is used to detect the Interferon, rabbit of formation or the ELISPOT of other cytokine measures with serum.When identification antigenic stimulation T cell (splenocyte or PBMC) time, the IFN-gamma antibodies is caught the IFN-γ of any generation.Therefore, after washing unconjugated material off, the IFN-γ of formation keeps being incorporated into IFN-γ capture antibody, and can obtain detecting with bonded IFN-γ bonded second antibody by adding.This second antibody is carried out mark, with easy observation.

[0173] substratum of Shi Yonging can be to contain penicillin/streptomycin/glutamine, and has replenished the Dulbecco substratum that 10-50 μ g/ml PXB improves with the Iscove that suppresses any contaminative LPS.For mouse T raji cell assay Raji, also in substratum, replenish 2 mercapto ethanol, reach 5 * 10 ^-5The final concentration of M.Be used for positive control antigen that the people measures can comprise with 1/160 use be adsorbed on Toxoid,tetanus on the alum (Colorado Serum Co), in the donor of TB inoculation, be the protein derivatives (from the Tubersol of Aventis Pasteur) of purifying.Can be used to confirm that the mitogen of measuring with cell viability comprises concanavalin A that is used for mouse cell and the phytohaemagglutinin that is used for people's cell, all be to use with 1 μ g/ml.Carrying out antibody that IFN-γ detects by ELISPOT is right from the coupling of Pharmingen.

[0174] after 18-20 hour common cultivation, detects antibody (Pharmingen) with biotinylated anti-IFN-γ and detect the Interferon, rabbit of catching, and, manifest with nitro-BT photographic developer then with streptavidin-alkaline phosphatase.Also got the supernatant liquor of people and mouse culture at 6 hours, 12 hours, 24 hours and 48 hours, carry out cell multiplex factorial analysis (using 10 heavy test kits) from the routine of Linco Research Inc, to analyze Th1 (IFN-γ, TNF-α and IL-12), Th2 (IL-4, IL-6, IL-1 0 and IL-13) and inflammatory cytokine (IL-I β, IL-2 and GM-CSF), and can analyze simultaneously with Luminex 100 instruments.The existence of one or more described cytokines has proved the protein induced cellullar immunologic response that detects, and makes it possible to identify the albumen or the peptide that are used for induction of immunity.

Embodiment 10

Detect t cell activation with the protein expression among the APCs

[0175] the most protein groups of the biology that will consider (as vaccinia virus) is cloned in CMV (gWIZ) carrier.Send to pass with plasmid and (, adopt special lipid reagent, as Lipofectin from Invitrogen by " Lipofection " ^TM, Bio-Rad Cytofectene ^TMTransfection reagent, or the FuGENE 6 of Roche Applied Science ^TMTransfection reagent; Referring to Feigner, et al, Proc.Nat ' l.Acad.Sci.USA.Nov.1987 84 (21), 7413-7 is hereby incorporated by) plasmid is imported antigen presenting cell (APCs).After 1 day, make protein expression, mix the T cell with 96 well format then.From pathogenic agent (as intraperitoneal give 2 * 10 ⁵The pfu vaccinia virus) subcutaneous each recombinant protein mice immunized that gives of intraperitoneal or tail basis pontis obtains or in adjuvant, or obtains to reply the T cell from people's donor of infected/immunity.Under the situation of mouse, the immunity back was taken out spleen or draining lymph node in 7-10 days.Then the antigen presenting cell of transfection is added mice spleen cell or human peripheral blood mononuclear cell (PBMC in Multiscreen 96 orifice plates (Millipore MAHAS45) of using anti-mouse or people IFN-γ (from Pharmingen) bag quilt in advance; 5 * 10 ⁵Cells/well), in the tissue culture medium (TCM) that contains 10% foetal calf serum (FCS) (mouse mensuration) or 5% people AB serum (people's mensuration), sealed 1 hour.

[0176] substratum of Shi Yonging can be to contain penicillin/streptomycin/glutamine, and has replenished the Dulbecco substratum that 10-50 μ g/ml PXB improves with the Iscove that suppresses any contaminative LPS.For mouse T raji cell assay Raji, also in substratum, replenish 2 mercapto ethanol, reach 5 * 10 ^-5The final concentration of M.Be used for positive control antigen that the people measures can comprise with 1/160 use be adsorbed on Toxoid,tetanus on the alum (Colorado Serum Co), in the donor of TB inoculation, be the protein derivatives (from the Tubersol of Aventis Pasteur) of purifying.Can be used to confirm that the mitogen of measuring with cell viability comprises concanavalin A that is used for mouse cell and the phytohaemagglutinin that is used for people's cell, all be to use with l μ g/ml.Carrying out antibody that IFN-γ detects by ELISPOT is right from the coupling of Pharmingen.

[0177] after 18-20 hour common cultivation, detects antibody (Pharmingen) with biotinylated anti-IFN-γ and detect the Interferon, rabbit of catching, and, manifest with nitro-BT photographic developer then with streptavidin-alkaline phosphatase.Also got the supernatant liquor of people and mouse culture at 6 hours, 12 hours, 24 hours and 48 hours, carry out cell multiplex factorial analysis (using 10 heavy test kits) from the routine of Linco Research Inc, to analyze Th1 (IFN-γ, TNF-α and IL-12), Th2 (IL-4, IL-6, IL-1 0 and IL-13) and inflammatory cytokine (IL-I β, IL-2 and GM-CSF), and can analyze simultaneously with Luminex 100 instruments.The existence of one or more described cytokines has proved the protein induced cellullar immunologic response that detects, and makes it possible to identify the albumen or the peptide that are used for induction of immunity.

Embodiment 11

With plasmodium (plasmodium falciparum) checking antigen authentication method

[0178] select one group 218 kinds plasmodium falciparums (Pf) gene to be used for clone, expression and the printing of arrays of immobilized protein chip.Based on Subcellular Localization (as excretory albumen and be present in other albumen in the cell culture supernatant liquid), known immunogenicity in the humans and animals model of plasmodium falciparum and the model selection gene of genetic expression and growth of malaria parasites state.Each all is fit to one of nine classes: i) only identify (n=25) by the information biology standard; Ii) identify and in the sporozoite protein group, identify (n=16) by MudPIT by by stages laser capture micro-dissection in the Plasmodium yoelii liver; Iii) the proteic Pf that identifies by by stages laser capture micro-dissection in the Py liver is directly to homologue, but is not present in the sporozoite protein group (specific by stages in the liver; N=52); Iv) identify at sporozoite protein group camber and express (n=10) by MudPIT; V) in the sporozoite protein group, identify, and measure the origin immunity identification (n=27) that volunteer's the PBMCs of sporozoite (irr-spz) immunity of overshoot produces of hanging oneself by MudPIT; The vi) Pf antigen (n=21) of known and abundant sign in the clinical development; Vii) sporozoite is carried out genetic transcription spectrum analysis proof and express (n=53) at the interim height of sporozoite by the Affymetrix gene chip; Viii) in trophont and schizont phase protein groups, identify (n=11) by MudPIT; And ix) shows that the plasmodium falciparum of the Plasmodium yoelii that has protectiveness in vivo is directly to homologue (n=2).A kind of extra interested gene PFB0645c that comprises is not suitable for any described classification.

[0179] carries out pcr amplification with plasmodium falciparum genomic dna template.Because a lot of plasmodium falciparum genes contain intron, have designed the primer of striding each exon.With the big gene (and exon) of pieces amplification above 3000 base pairs, overlapping 150 Nucleotide of each fragment (i.e. 50 amino acid).Cover the genomic design of primers of whole plasmodium falciparum by the genome of UC Irvine and the ArIo Randall of bioinformation institute, can read the primer database by web interface.This database contains 14,446 kinds of entities.Therefore, for each the independently exon and the big gene that amplification exists with the fragment less than 3000 bp of increasing, need 14,446 primers right.But about 40% ORFs coding is less than 50 amino acid whose small peptides, and each ORF greater than 150 Nucleotide that therefore increases needs about 8000 primers right.With the primer sequence source of this online database as following research.

[0180] increases, clones and express 266 ORFs altogether that derive from 218 gene target groups with previously described expression system.Having adopted needs the method that finish in 3 days, from plasmodium falciparum genomic dna pcr amplification 266 ORFs, fragment cloning in the T7 expression vector, is expressed in acellular in-vitro transcription/translation system, with the expressed proteins point sample to micro-array chip.The intestinal bacteria lysate detection chip that the serum of human volunteer of sporozoite immunity of overshoot of being used for hanging oneself is handled makes the slide glass colour developing, usefulness confocal laser micro-array chip reader reading with anti-people's antibody of Cy3 mark.The plasmodium falciparum albumen test of a plasmodium immune body and a subgroup, and not contacted antigenic individuality does not react.Albumen is printed onto on the micro-array chip, uses the serum detection chip from 11 donors, described donor Natural Exposure is in the malaria in Kenya high incidence district, or once with the sporozoite immunity of radiation.Not contacted antigenic donor lacks the reactivity (Fig. 6) to the one group of complete expressing protein that prints on the chip, but from the serum of the individuality of immunity and the subgroup albumen test on the chip.These results' general introduction is shown in table 4." locus " code representative in the table 4 is corresponding to " locus label " code that uses in the GenBank database, and this database can onlinely obtain, and network address is www.ncbi.nlm.nih.gov/gquery/gquery.fcgi.Therefore, can be easily obtain in the table every kind of proteic dna sequence dna and peptide sequence with these codes.

[0181] from this Analysis and Identification 9 kinds of strong reactive proteins.In the proteins C reactive 7 kinds of 9 kinds of height are Pf blood stage antigens known, abundant sign, wherein much carrying out clinical development and assessment (LSA3, MSP4, EBA175, RESA).What is interesting is, PF10_0356, promptly stage antigens 1 is a phase specific antigens in the liver in the liver; It is not expressed in the sporozoite or the blood phase of biology, and only the phase expresses in liver.Therefore, 6 parts of these antigenic facts of serum identification in 11 parts of serum have proved that the protein groups array has the ability of not only identifying the blood stage antigens.Equally, PFD0310w is SHEBA/Pfsl6, promptly a kind of sexual stage antigens that is carrying out clinical development as the vaccine antigen material standed for.Have one of antigen of strong reactivity, i.e. PFE1590w, not being realized in the past is possible vaccine antigen material standed for.

Serum reactivity among the experimenter of table 4. plasmodium immunity

The number of reactor	Locus	Protein name
				11	PFB0300c	Merozoite surface protein 2 precursors (MSP2)
11	PFB0915w *	Stage antigens 3 (LSA3) in the liver
			10	PFB0310c *	Merozoite surface protein 4 (MSP4)
9	PFE1590w	The membranin of early transcription
			8	PFD0310w	Sexual phase specific proteins precursor (SHEBA/Pfs16)
6	PF07_0128	Erythrocyte binding antigen (EBA175) 75)
			6	PF10_0343 *	S-antigen
6	PF10_0356	Stage antigens in the liver, (LSA1) of supposition
			6	PF11_0509 *	The erythrocyte surface antigen (RESA) that ring infects

^*These genes comprise intron, and are expressed as two independently albumen, they are overlapping 20 amino acid.At least a in these two kinds of albumen is antigenic.

[0182] only be for example, rather than the albumen that the present invention includes of restriction or the scope of dna sequence dna, some nearest directly comprising of some immunoreactive proteins that do not comprise in the table 4, identify by method of the present invention to homologue:

[0183]PFB0310c：

Plasmodium yoelii: PY05967 (MSP4/5 is correlated with)

Plasmodium yoelii: PY07543 (MSP 4/5)

[0184]PFE1590w：

Plasmodium yoelii: PY02667 (conformity membrane albumen)

[0185]PFB07_0128：

Plasmodium falciparum: Chr.13, MAL13P1.60 (erythrocyte binding antigen 140)

Plasmodium falciparum: Chr.1, PFA0125c (Ebl-1 sample albumen, supposition)

Plasmodium falciparum: Chr.1, PFA0065w (putative protein)

Plasmodium falciparum: Chr.4, PFD1155w (erythrocyte binding antigen, supposition)

Plasmodium yoelii: PY04764 (duffy acceptor, β type precursor)

[0186]PF10_0343：

Plasmodium yoelii: PY04926 (putative protein)

[0187]PF11_0509：

The explanation of gene species

MAL6P1.19 plasmodium falciparum putative protein

MAL7P1.174 plasmodium falciparum putative protein

MAL7P1.7 plasmodium falciparum RESA-sample albumen

The MAL8P1.2 plasmodium falciparum has the putative protein of DNAJ structural domain

PF10_0378 plasmodium falciparum putative protein

PF11_0037 plasmodium falciparum putative protein

The erythrocyte surface antigen that PF11_0509 plasmodium falciparum ring infects, supposition

The erythrocyte surface antigen 2 that PF11_0512 plasmodium falciparum ring infects, RESA-2

Plasmodium (plasmodium falciparum) is relevant

PF11_0513 plasmodium falciparum putative protein

PF14_0018 plasmodium falciparum putative protein

PF14_0732 plasmodium falciparum putative protein

PF14_0746 plasmodium falciparum putative protein

The erythrocyte surface antigen precursor that PFA0110w plasmodium falciparum ring infects

PFB0080c plasmodium falciparum putative protein

PFB0085c plasmodium falciparum putative protein

PFB0920w plasmodium falciparum putative protein

PFD0095c plasmodium falciparum putative protein

PFD1170c plasmodium falciparum putative protein

PFD1180w plasmodium falciparum plasmodium falciparum trophont antigen sample albumen

PFE1600w plasmodium falciparum putative protein

The PFE1605w plasmodium falciparum has the albumen of DNAJ structural domain

PFI0130c plasmodium falciparum putative protein

PFI1785w plasmodium falciparum putative protein

PFI1790w plasmodium falciparum putative protein

The PFL0055c plasmodium falciparum has the albumen (resa sample) of DNAJ structural domain, supposition

PFL2535w plasmodium falciparum RESA sample albumen, supposition

PFL2540w plasmodium falciparum putative protein

[0188]PF13_0197：

Plasmodium falciparum: CHR 13/MAL13P1.173/MSP7-sample albumen

Plasmodium falciparum: CHR 13/MAL13P1.174/MSP7-sample albumen

Plasmodium falciparum: CHR 13/PF13_0193/MSP7-sample albumen

Plasmodium falciparum: CHR 13/PF13_0196/MSP7-sample albumen

Plasmodium falciparum: CHR 13/PF13_0197/ merozoite surface protein 7 precursors,

MSP7

Plasmodium yoelii: PY02147/ Meloidogyne incognita COL-1 is correlated with

[0189]PF14_0486：

Plasmodium yoelii: PY05356 (elongation factor 2)

[0190]PF08_0054：

Plasmodium yoelii: PY06158 (heat shock protein 70)

[0191]PF11_0344：

Plasmodium yoelii: PY01581 (apical membrane antigen-1)

[0192] in the application separately of these methods, expresses and 300 kinds of genes with method described herein, and on array, show from plasmodium falciparum.Use serum detection array from 12 experimenters, the contacted in early days malaria of described experimenter, and therefore this has been produced immunity.For following each gene product, we observe in 12 serum samples at least 6 and have positive reaction:

Serum reactivity among the experimenter of table 4b. plasmodium immunity

Gene (the locus label that is used for GenBank)	Explanation from GenBank	Reactor (12 reactor number in serum)
			PFB0915w	LSA-3-e2s1	12
PFB0310c	MSP-4-e1	12
			PFB0300c	MSP-2	12
PFB0305c	MSP-5-e1	12
			PFL2410w	Putative protein-e1	12
PFC0210c	Ring spore (CS) albumen	12
			PFD0310w	Sexual phase specific proteins precursor a	11
PFD0310w	Sexual phase specific proteins precursor b	11
			PF13_0197	The MSP7 precursor	11
PF10_0138	Putative protein-s1	11
			PFI1520w	Putative protein b	11
PFI1520w	Putative protein a	11
			PF11_0344	Apical membrane antigen 1 precursor	11
PF13_0012	Putative protein	10
			PFD0310w	Sexual phase specific proteins precursor	10
PF11_0358	Be oriented to the RNAP of DNA, B subunit-e1	10
			PF07_0029	HSP86-e1	10
PFL1605w	Putative protein-s2	10
			PFE1590w	Early stage transmembrane protein	10
MAL6P1.201	Leucyl-trna synthetic enzyme, tenuigenin-s2	10
			PFD0235c	Putative protein-e1	9
PF13_0201	Sporozoite surface protein 2	9
			PF13_0267	Putative protein a	9
PF07_0128	Erythrocyte binding antigen-e1s2	9
			PF10_0343	S-antigen a	9
PF10_0343	S-antigen	9
			PFI1520w	Putative protein	8
PFI0580c	Terminal signal peptide-the e2 of the albumen w/N that is rich in Asn that supposes	8
			PF07_0020	Putative protein-e1s2	8

PFE0520c	Topoisomerase I	8
			MAL7P1.29	Putative protein-e1s2	8
PF10_0260	Putative protein-e2s2	8
			PF11_0358	Be oriented to the RNAP of DNA, B subunit-e2s2	7
MAL8P1.139	Putative protein-e3	7
			PF13_0228	PF01092Rib Protein S 6e	7
PF10_0132	Phospholipase C sample-e1s2	7
			PFB0855c	Putative protein-e2	7
PF10_0125	Putative protein	7
			PF13_0350	SRP54 type albumen, GTP enzymatic structure territory	7
PFD0665c-e2		7
			MAL7P1.32	Putative protein	7
PF07_0016	Putative protein-s1	7
			PF10_0098a		6
PF08_0056	Zinc finger protein-e2	6
			PFB0640c-e1s1		6
PF14_0230	Rib protein family L5-e2	6
			PF14_0315	Putative protein-e2s1	6
PF08_0088	Putative protein	6
			PFL0685w	Putative protein-e2	6
MAL7P1.23	Putative protein-e1s2	6
			PFE0060w	Putative protein-e2	6
MAL8P1.23	Ubiquitin ligase enzyme 1-s8	6
			PF07_0029	HSP86-e2	6
PF10_0356	LSA-e2s2	6

Embodiment 12

Malaria vaccine and diagnostic test

[0193] from the data set that embodiment 11 obtains, select the cocktail of the nucleic acid of albumen or proteins encoded, be used for vaccine component.Malaria vaccine cocktail based on these results comprises gene below at least three kinds or corresponding peptides, or four kinds or more, or five kinds or more, or comprise all following these: PFB0300c, PFE1590w, PFB0915w, PFB0310c, PFB0310w, PF11_0509 and PF10_0343.With this vaccine of vehicle disclosed herein, composition and method afford, so that the human experimenter with malariated danger is carried out immunity, prerequisite is that this experimenter's immunity system is not damaged.

[0194] or, vaccine comprises at least three kinds of nucleic acid or three kinds of albumen corresponding to genes identified in the table 4, as proteic gene of antigen expressed or albumen.In a kind of preferred embodiment, vaccine comprise in these albumen or the nucleic acid more than three kinds or more than four kinds, or at least six kinds.Typically, vaccine comprises at least three kinds of nucleic acid or albumen corresponding to specific gene, and described specific gene product is at the serum of at least 6 parts of tests or the serum of at least 8 parts of tests; Or the serum of at least 9 parts of tests; Or the serum of at least 10 parts of tests; Or or the serum of at least 11 parts of tests in produce positive reaction.In some embodiments, vaccine comprises at least a composition corresponding to one of gene of inducing positive reaction in the serum of 10 parts or more parts of tests.In other embodiments, vaccine comprises at least two kinds or at least three kinds corresponding to the albumen or the nucleic acid component of inducing the gene of positive reaction in 10 parts in 12 parts of serum of test or the more parts of serum.In another embodiment, immunodominance antigen is used for the serodiagnosis test, as ELISA,, or be subjected to its infection so that whether the individuality of clarifying a diagnosis once was exposed to plasmodium falciparum.

Embodiment 13

Draw the antigenic protein of identifying in the hot Frances Salmonella at soil

[0195] after adopting the albumen that draws the embodiment 1D of hot Frances Salmonella from soil to carry out method mentioned above, identified some and mouse, or the serum that comes from the mouse that is exposed to the SchuS4 bacterial strain with virulence has reactive antigenic protein from the non-infectious bacterial strain that is exposed to the Frances Salmonella.These proteic data vide infra table 5 and 6.Proteic sequence can obtain from the GenBank database, and this database can onlinely obtain, and network address is www.ncbi.nlm.nih.gov/gquery/gquery.fcgi.Genetic code in the table is corresponding to genes identified and proteic locus label.

The antigen of table 5. from the serum detection of the mouse that is exposed to non-infectious bacterial strain

		Be exposed to the mouse (every row are represented 5-6 mouse) of non-infectious bacterial strain
						Albumen	Gene
	1 to 6	7 to 12	13 to 17	18 to 22
					DnaK(HSP70)	FTT1269	x		x	x
TM albumen (OmpH)	FTT1747	x	x	x							x
					HSP60(Cpn60)	FTT1696	x			x
TM albumen	FTT0975	x		x							x
					17kd albumen (IpnA)	FTT0901
	FTT0901	x									x
						FTT1477
Biotin carboxyl carrier	FTT0472	x									x
						FTT0264

The antigenic protein of table 6. from the serum detection of the mouse of Schu S4 invasion and attack

		The mouse set of Schus4 invasion and attack (every row representative is from the serum of 5-6 mouse)
						Albumen	Gene		1 to 6	7 to 12	13 to 17	18 to 22
DnaK(HSP70)	FTT1269	x	x	x	x
						TM albumen (OmpH)	FTT1747	x	x	x	x
HSP60(Cpn60)	FTT1696	x	x	x	x
						1272SS TM albumen	FTT0975	x	x		x
17kd albumen (IpnA)	FTT0901	x
							FTT0901	x
	FTT1477	x	x
						Biotin carboxyl carrier	FTT0472				x
	FTT0264				x

[0196] go up table and shown with the mouse of the biological attack that virulence is arranged and produced more antibody than the mouse with non-infectious bacterial strain invasion and attack only, some production of antibodies is unusual unanimity, no matter and with which bacterial strain immune mouse.

[0197] only be for example, rather than the albumen that the present invention includes of restriction or the scope of dna sequence dna, some nearest variants of some immunoreactive proteins of identifying by method of the present invention and directly comprising to homologue:

[0198]FTT1269(DnaK)：

Pseudomonas aeruginosa PAO1

Pseudomonas putida KT2440

Legionella pneumophilia

Bai Shi cock steadite RSA 493 strains

Legionella pneumophilia Lens strain

Legionella pneumophilia Paris strain

Bai Shi cock steadite dnaK

Legionella pneumophilia grpE, dnaK, dnaJ

The intestines Salmonellas

Intestines Salmonellas serovar typhoid fever (salmonella typhi) CT18 strain

[0199]FTT1696(Hsp60)：

Acinetobacter calcoaceticus kind ADP1

Xenorhabdus nematophilus GroEL sample protein gene

Vibrio cholerae O 1 eltor biovar N16961 strain karyomit(e) I

Pseudomonas aeruginosa PAO1

The Klebsiella pneumonia gene of GroES albumen homology thing, GroEL albumen homology thing

The enterobacter agglomerans gene of GroES albumen homology thing, GroEL albumen homology thing

The enterobacter asburiae gene of GroES albumen homology thing, GroEL albumen homology thing

Pseudomonas aeruginosa GroEL (mopA) gene

The enteroaerogen gene of GroES albumen homology thing, GroEL albumen homology thing

The Pseudoalteromonas kind PS1M3 gene of GroES, GroEL

[0200] FTT0901 (17kd albumen)

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor albipictus clone T1G

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor variabilis clone 01-109

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor occidentalis clone 02-241

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor hunteri clone 01-113

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor andersoni clone 01-151-1

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor andersoni clone 01-171

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor nitens clone DnT2-1

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor hunteri clone 02-249

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor hunteri clone 01-112

The Frances Salmonella endosymbiont 17kDa lipoprotein gene of Dermacentor andersoni clone 02-31

[0201]FTT1477c：

Pseudomonas putida KT2440

The mutation DC3000 strain of causing a disease of pseudomonas syringae tomato

Pseudomonas aeruginosa PAO1

Carpetweed Xanthomonas campestris citri mutation 306 strains of causing a disease

Mutation ATCC 33913 strains of causing a disease of xanthomonas campestris bird rape

Photobacterium profundum SS9

Pod membrane methyl coccus Bath strain

Legionella pneumophilia Paris strain

Legionella pneumophilia Lens strain

The living slowly root nodule bacterium USDA of soybean 110DNA

[0202] FTT0472 (biotin carboxyl carrier):

Pseudomonas aeruginosa PAO1

Pseudomonas aeruginosa biotin carboxyl carrier protein and biotin carboxylase (accB and accC) gene

Legionella pneumophilia is had a liking for lung subspecies Philadelphia 1 strain

Legionella pneumophilia Paris strain

Multocida kills subspecies Pm70 strain more

Legionella pneumophilia Lens strain

Pod membrane methyl coccus Bath strain

Shigella flexneri 2a strain

Salmonella typhimurium LT2

Shigella flexneri 2a 2457T strain

Embodiment 14

Antigenic protein from mycobacterium tuberculosis

[0203], used from the Identification of Fusion Protein of the embodiment 1C of mycobacterium tuberculosis H37Rv following albumen (selected known variant and directly also show) as limiting examples to homologue according to above-described method:

[0204] Rv3333c (albumen of the proline rich of supposition)

Variant/directly to homologue: Mb2765c (Mycobacterium bovis)

ML0981 (Mycobacterium leprae)

[0205] Rv0440 (60kDa chaperone)

Variant/directly to homologue: Mb0448 (Mycobacterium bovis)

ML0317 (Mycobacterium leprae)

[0206] Rv1860 (being rich in the excretory albumin A PA of L-Ala and proline(Pro))

Variant/directly to homologue: Mb1891 (Mycobacterium bovis)

[0207] Rv3763 (19kDa lipoprotein antigen precursor LPQH)

Variant/directly to homologue: Mb3789 (Mycobacterium bovis)

MLI 966 (Mycobacterium leprae)

[0208] Rv3874 (10kDa culture filtrate antigen ESXB)

Variant/directly to homologue: Mb2765c (Mycobacterium bovis)

[0209] Rv3875 (the early stage secretion antigen target of 6kDa ESXA)

Variant/directly to homologue: Mb3905 (Mycobacterium bovis)

Embodiment 15

Antigenic protein from mycobacterium tuberculosis

[0210] adopts method mentioned above and the albumen of the gene that obtains from embodiment 1C, use from the serologic test of rabbit, mouse and monkey albumen from the gene of 312 kinds of expression of mycobacterium tuberculosis H37Rv.Following table has been listed and has been used the antigen that detects from the serum of each species: by the locus label of the corresponding gene that adopts in the public obtainable GenBank database, identify every kind of albumen.The not serum of infected animals and all antigen-reactives of listing; List and emphasized only to be used for the antigen that the serum of animal of self-infection TB detects with runic.

Table 7

Rabbit	Mouse	Monkey
			Rv0040	Rv0040	Rv0440
Rv0292	Rv0102	Rv0475
			Rv0432	Rv0292	Rv0577
Rv0674	Rv0366c	Rv1801
			Rv0867c	Rv0432	Rv1860
Rv1004c	Rv0440	Rv1980c

Rabbit	Mouse	Monkey
			Rv1157c	Rv0467	Rv220
Rv1184c	Rv0529	Rv2744c
			Rv1310	Rv0538	Rv2873
Rv1435c	Rv0545c	Rv2875
			Rv1620c	Rv0685	Rv3270
Rv1733c	Rv0798c	Rv3333c
			Rv1801	Rv0847	Rv3418c
Rv1837c	Rv0886	Rv3763
			Rv1860	Rv0916c	Rv3873
Rv2031c	Rv0934	RV3874
			Rv2190c	Rv1004c	Rv3875
Rv2195	Rv1244	The Rv3875﹠Rv3874 syzygy
			Rv2253	Rv1307	Rv3881c
Rv2376c	Rv1311
			Rv2700	Rv1435c
Rv2721c	Rv1451
			Rv2744c	Rv1666c
Rv2744c	Rv1620c
			Rv2864c	Rv1623c_1
Rv3270	Rv1686c
			Rv3333c	Rv1733c
Rv3449	Rv1737c
			Rv3873	Rv1860
	Rv1906c
				Rv1926c
	Rv1984c
				Rv2007c
	Rv2031c
				Rv2193
	Rv2195
				Rv2196
	Rv2253
				Rv2376c
	Rv2389c
				Rv2446c
	Rv2495c
				Rv2620c
	Rv2700
				Rv2744c
	Rv2873
				Rv2875
	Rv3217c
				Rv3270
	Rv3330
				Rv3333c
	Rv3390

Rabbit	Mouse	Monkey
				Rv3418c
	Rv3524
				Rv3705c
	Rv3714c
				Rv3803c
	Rv3828c
				Rv3841
	Rv3846
				Rv3873
	Rv3874
				Rv3875
	Rv3881c
				Rv3914

Embodiment 16

Vaccinum Calmette-Guerini and diagnostic test

[0211] from the data set that embodiment 15 obtains, select the cocktail of the nucleic acid of albumen or proteins encoded, be used for vaccine component.Tuberculosis diagnostic test or vaccine cocktail based on these results comprise gene below at least three kinds or corresponding peptides, and can comprise four kinds or more, or five kinds or more, or comprise following these most of or all: Rv0440, Rv0467, Rv0475, Rv0538, Rv0674, Rv0685, Rv0798c, Rv0916c, Rv0934, Rv1801, Rv1860, Rv1926c, Rv1980c, Rv1984c, Rv2007c, Rv2031c, Rv2190c, Rv2220, Rv2376c, Rv2389c, Rv2446c, Rv2744c, Rv2873, Rv2875, Rv2875, Rv3270, Rv3330, Rv3333c, Rv3418c, Rv3763, Rv3803c, Rv3828c, Rv3846, Rv3874, Rv3875, Rv3881c and Rv3914.Specially suitable antigen comprises and those antigens from the serological specificity reaction of the infected animals of a plurality of species, comprises Rv0440, Rv1801, Rv2031c, Rv2376c, Rv2875 and Rv3875.Interested especially by the antigen of discerning from the serological specificity of infected monkey, comprise Rv0440, Rv0475, Rv1801, Rv1980c, Rv2220, Rv2873, Rv2875, Rv3270, Rv3763 and Rv3875.Therefore, vaccine or diagnostic test can comprise be selected from these groups antigenic two or more, or three kinds or more, or albumen more than three kinds or nucleic acid.

[0212] with this vaccine of vehicle disclosed herein, composition and method afford, so that the human experimenter with danger of infecting tuberculosis is carried out immunity, prerequisite is that this experimenter's immunity system is not damaged.

Table 8

The locus title	VACV-COP is directly to homologue	Size	Chain	Initial	Finish
						VACWR129	A10L	891	-	121844	119169
VACWR130	A11R	318	+	121859	122815
						VACWR131	A12L	192	-	123395	122817
VACWR132	A13L	70	-	123631	123419
						VACWR133	A14L	90	-	124011	123739
VACWR135	A15L	94	-	124463	124179
						VACWR136	A16L	377	-	125580	124447
VACWR137	A17L	203	-	126194	125583
						VACWR138	A18R	493	+	126209	127690
VACWR139	A19L	77	-	127904	127671
						VACWR119	A1L	150	-	110357	109905
VACWR141	A20R	426	+	128257	129537
						VACWR140	A21L	117	-	128258	127905
VACWR142	A22R	187	+	129467	130030
						VACWR143	A23R	382	+	130050	131198
VACWR144	A24R	1164	+	131195	134689
						VACWR145	A25L	65	-	134891	134894
VACWR146	A26L-a	154	-	135324	134860
						VACWR148	ATI locus albumen		-	136239	138416
VACWR149	A26L-b	500	-	139963	138461
						VACWR150	A27L	110	-	140345	140013
VACWR151	A28L	146	-	140786	140346
						VACWR152	A29L	305	-	141704	140787
VACWR120	A2L	224	-	111052	110378
						VACWR153	A30L	77	-	141900	141667
VACWR154	A31R	124	+	142060	142434
						VACWR155	A32L	270	-	143213	142401
VACWR156	A33R	185	+	143331	143888
						VACWR157	A34R	188	+	143912	144418
VACWR158	A35R	176	+	144462	144992
						VACWR159	A36R	221	+	145059	145724
VACWR160	A37R	263	+	145788	146579
						VACWR162	A38L	277	-	147687	146854
VACWR164	A39R	142	+	148474	148902
						VACWR122	A3L	644	-	113228	111294
VACWR165	A40R	159	+	148928	149407
						VACWR166	A41L	219	-	150164	149505
VACWR167	A42R	133	+	150328	150729

The locus title	VACV-COP is directly to homologue	Size	Chain	Initial	Finish
						VACWR168	A43R	194	+	150767	151351
VACWR170	A44L	346	-	152733	151693
						VACWR171	A45R	125	+	152780	153157
VACWR172	A46R	240	+	153147	153869
						VACWR173	A47L	252	-	154675	153917
VACWR174	A48R	227	+	154706	155389
						VACWR175	A49R	162	+	155437	155925
VACWR123	A4L	281	-	114126	113281
						VACWR176	A50R		552	+	155958	157616
VACWR177	A51R	334	+	157669	158673
						VACWR178	A52R		190	+	158743	159315
VACWR179	A53R	103	+	159621	159932
						VAGWR180	A55R	564	+	160439	162133
VACWR181	A56R	314	+	162183	163127
						VACWR182	A57R	151	+	163272	163727
VACWR124	A5R	164	+	114164	114658
						VACWR125	A6L	372	-	115773	114655
VACWR126	A7L	710	-	117929	115797
						VACWR127	A8R	288	+	117983	118849
VACWR128	A9L	108	-	119168	118842
						VACWR192	B10R	166	+	171672	172172
VACWR193	B11R	72	+	172244	172462
						VACWR194	B12R	283	+	172529	173380
VACWR195	B14R	345	+	173473	174510
						VACWR196	B15R	149	+	174585	175034
VACWR197	B16R	326	+	175118	176098
						VACWR198	B17L	340	-	177166	176144
VACWR199	B18R	574	+	177306	179030
						VACWR203	B18R	309	+	180898	181827
VACWR200	B19R	351	+	179102	180157
						VACWR183	B1R	300	+	163878	164780
VACWR202	B20R		53	+	180482							180643
						VACWR184	B2R	219	+	164870	165529
VACWR185	B3R	167	+	165565	166068
						VACWR186	B4R		558	+	166594	168270
VACWR187	B5R	317	+	168374	169327
						VACWR188	B6R	173	+	169409	169930
VACWR189	B7R	182	+	169968	170516
						VACWR190	B8R	272	+	170571	171389

The locus title	VACV-COP is directly to homologue	Size	Chain	Initial	Finish
						VACWR191	B9R	77	+	171478	171709
VACWR209	C10L	331	+	185807	186802
						VACWR210	C11R	140	-	187379	186957
VACWR205	C12L	353	+	182511	183572
						VACWR206	C14L		190	+	183734	184306
VACWR017	C17L	71	-	12682	12467
						VACWR008	C19L	112	-	7060	6722
VACWR027	C1L	229	-	21832	21143
						VACWR212	C20L	109	+	188295	188624
VACWR006	C21L	84	-	6155	5961
						VACWR004	C22L	122	-	5460	5092
VACWR001	C23L	244	-	4375	3641
						VACWR026	C2L	512	-	21073	19535
VACWR025	C3L	263	-	19468	18677
						VACWR024	C4L	316	-	18610	17660
VACWR023	C5L	204	-	17597	16983
						VACWR022	C6L	151	-	16856	16401
VACWR021	C7L	150	-	16168	15716
						VACWR020	C8L	177	-	15644	15111
VACWR019	C9L	634	-	15068	13164
						VACWR115	D10R	248	+	104655	105401
VACWR116	D11L	631	-	107297	105402
						VACWR117	D12L	287	-	108195	107332
VACWR118	D13L	551	-	109881	108226
						VACWR106	D1R	844	+	93948	96482
VACWR107	D2L	146	-	96881	96441
						VACWR108	D3R	237	+	96874	97587
VACWR109	D4R	218	+	97587	98243
						VACWR110	D5R	785	+	98275	100632
VACWR111	D6R	637	+	100673	102586
						VACWR112	D7R		161	+	102613	103098
VACWR113	D8L	304	-	103975	103061
						VACWR114	D9R	213	+	104017	104658
VACWR066	E10R	95	+	56688	56975
						VACWR067	E11L	129	-	57359	56970
VACWR057	E1L	479	-	45443	44004
						VACWR058	E2L	737	-	47653	45440
VACWR059	E3L	190	-	48352	47780
						VACWR060	E4L	259	-	49187	48408

The locus title	VACV-COP is directly to homologue	Size	Chain	Initial	Finish
						VACWR061	E5R	341	+	49236	50261
VACWR062	E6R	567	+	50398	52101
						VACWR063	E7R	166	+	52183	52683
VACWR064	E8R	273	+	52808	53629
						VACWR065	E9L	1006	-	56656	53636
VACWR049	F10L	439	-	37778	36459
						VACWR050	F11L	348	-	38847	37801
VACWR051	F12L	635	-	40797	38890
						VACWR052	F13L	372	-	41949	40831
VACWR053	F14L	73	-	42188	41967
						VACWR054	F15L	147	-	42903	42460
VACWR055	F16L	231	-	43639	42944
						VACWR056	F17R		101	+	43702	44007
VACWR040	F1L	226	-	31026	30346
						VACWR041	F2L	147	-	31481	31038
VACWR042	F3L	480	-	32947	31505
						VACWR043	F4L	319	-	33917	32958
VACWR044	F5L	322	-	34917	33949
						VACWR045	F6L	74	-	35171	34947
VACWR046	F7L	80	-	35429	35187
						VACWR047	F8L	65	-	35774	35577
VACWR048	F9L	212	-	36472	35834
						VACWR078	G1L	591	-	70752	68977
VACWR080	G2R	220	+	71078	71740
						VACWR079	G3L	111	-	71084	70749
VACWR081	G4L	124	-	72084	71710
						VACWR082	G5R	434	+	72087	73391
VACWR084	G6R		165	+	73592							74089
						VACWR085	G7L	371	-	75169	74054
VACWR086	G8R	260	+	75200	75982
						VACWR087	G9R	340	+	78002	77024
VACWR099	H1L	171	-	87737	87222
						VACWR100	H2R	189	+	87751	88320
VACWR101	H3L	324	-	89297	88323
						VACWR102	H4L	795	-	91685	89298
VACWR103	H5R	203	+	91871	92482
						VACWR104	H6R	314	+	92483	93427
VACWR105	H7R	146	+	93464	93904
						VACWR070	I1L	312	-	60804	59866

The locus title	VACV-COP is directly to homologue	Size	Chain	Initial	Finish
						VACWR071	I2L	73	-	61032	60811
VACWR072	I3L	269	-	61842	61033
						VACWR073	I4L	771	-	64240	61925
VACWR074	I5L	79	-	64506	64267
						VACWR075	I6L	382	-	65673	64525
VACWR076	I7L	423	-	66937	65666
						VACWR077	I8R		676	+	66943	68973
VACWR093	J1R	153	+	80247	80708
						VACWR094	J2R	177	+	80724	81257
VACWR095	J3R	333	+	81323	82324
						VACWR096	J4R	185	+	82239	82796
VACWR097	J5L	133	-	83258	82857
						VACWR098	J6R	1286	+	83385	87225
VACWR032	K1L	284	-	25925	25071
						VACWR033	K2L	369	-	27256	26147
VACWR034	K3L	88	-	27572	27306
						VACWR035	K4L	424	-	28898	27624
VACWR037	K5L	134	-	29479	29075
						VACWR038	K6L	81	-	29693	29448
VACW R039	K7R	149	+	29832	30281
						VACWR088	L1R		250	+	77025	77777
VACWR089	L2R	87	+	77809	78072
						VACWR090	L3L	350	-	79114	78062
VACWR091	L4R	251	+	79139	79894
						VACWR092	L5R	128	+	79904	80290
VACWR030	M1L	472	-	24296	22878
						VACWR031	M2L	220	-	24936	24274
VACWR028	N1L	117	-	22172	21819
						VACWR029	N2L	175	-	22836	22309
VACWR068	O1L	666	-	59346	57346
						VACWR069	O2L	108	-	59720	59394

[0213] following examples are only used for illustrating certain embodiments of the present invention, therefore should not be construed as restrictive.Those skilled in the art should be understood that various versions, and therefore, these versions are also included within the scope of the present invention.It will be appreciated by those of skill in the art that a lot of aspects of the present invention described herein and embodiment can make up, and the present invention has specially comprised the described combination of many aspects described herein and embodiment.

Claims (67)

1. the method for the expression system of the nucleotide sequence that to need, this method comprises

Extract described expression system from the mixture of cell transformed;

Described mixture is to obtain by gather in the crops described cell from culture under the condition of not separating single clone; Described culture is by obtaining with the expression system of described nucleotide sequence or the composition transformed host cell of described expression system.

2. the process of claim 1 wherein that described expression system is included on the plasmid.

3. the method for claim 2, wherein said plasmid is that the homologous recombination in described cell obtains by nucleic acid that comprises described nucleotide sequence and linearizing plasmid.

4. the method for claim 3, wherein comprised at least one adapter, described adapter is complementary with at least one end of described linearizing plasmid, and, thereby control the directivity that described nucleotide sequence is connected with described linearizing plasmid with at least one terminal complementary polynucleotide of described nucleotide sequence.

5. the method for claim 4, wherein use two adapters, described adapter be with first terminal complementary first adapter of the first terminal and described nucleotide sequence of described linearizing plasmid and with second end of described linearizing plasmid and second terminal complementary second adapter of described nucleotide sequence.

6. the process of claim 1 wherein that nucleotide sequence is connected with the sequence operability that promotor, terminator sequence or coding merge mark or signal peptide.

7. the method for claim 6, wherein said fusion mark is polyhistidine tag, hemagglutinin mark, Biotin-ligase recognition site, GST mark, fluorescent protein labeling, FLAG mark or joint sequence.

8. preparation contains the method for plasmid of expression system of the nucleotide sequence of needs, this method comprises with the nucleic acid and the linearizing plasmid transformed host cell that comprise described nucleotide sequence, the amount of wherein said nucleic acid and linearizing plasmid is each 1,000,000 cell 1-10ng nucleic acid, and wherein said nucleic acid and linearizing plasmid pass through pcr amplification, cell transformed with the reorganization that to realize described nucleic acid and described linearizing plasmid makes described plasmid contain described expression system.

9. the method for claim 8 has wherein been used at least one ten million described cell.

10. the method for claim 8, wherein said cell is chemoreception attitude cell and/or comprises intestinal bacteria or yeast.

11. the method for claim 10, wherein said intestinal bacteria are selected from JC8679, TB1, DH5 α, DH5, HB101, JM101, JM109 and LE392.

12. the method for claim 8 further comprises from cell transformed and extracts the described plasmid that contains described expression system.

13. the method for claim 1 or 8 further comprises and expresses described nucleotide sequence, so that obtain encoded protein or peptide in deriving from the system of cell.

14. the method for claim 13, the wherein said system that derives from cell is a cell free system.

15. the method for claim 14, wherein cell free system is to derive from transcribing/translation system of microorganism, eukaryotic cell or wheat germ.

16. the method for claim 13, the wherein said system of cell that derives from is at cell interior.

17. the method for claim 16, wherein said cell are antigen presenting cell (APC).

18. the method for claim 17, wherein said APC is selected from scavenger cell, dendritic cell and B cell.

19. the method for claim 13, wherein said expression are the expression of multiple nucleotide sequence, to obtain multiple protein or peptide.

20. the method for claim 19, wherein said multiple protein or peptide are by the genome encoding of infectious agent.

21. the method for claim 20, wherein said multiple protein or peptide are applied on the test surfaces, to obtain albumen/peptide array.

22. the method for claim 21, wherein said multiple protein or peptide have obtained representing albumen/peptide array of at least 50% of described infectious agent whole genome.

23. the method for claim 21, wherein said multiple protein or peptide have obtained representing albumen/peptide array of at least 98% of described infectious agent whole genome.

24. being vaccinia virus, soil, the method for claim 21, wherein said infectious agent draw hot Frances Salmonella, human papillomavirus, west Nile virus, pseudoglanders bulkholderia cepasea, mycobacterium tuberculosis or plasmodium falciparum.

25. peptide/protein arrays by the preparation of the method for claim 21.

26. a peptide/protein arrays, it contains albumen and the peptide of representing infectious agent genomic at least 50%, and wherein said array comprises at least 100 kinds of different albumen or peptide.

27. the peptide/protein arrays of claim 25, it represents at least 98% of described infectious agent whole genome.

28. being vaccinia virus, soil, the peptide/protein arrays of claim 26, wherein said infectious agent draw hot Frances Salmonella, human papillomavirus, west Nile virus, pseudoglanders bulkholderia cepasea, mycobacterium tuberculosis or plasmodium falciparum.

29. identify and have the method for immunocompetent albumen or peptide, this method comprises that the albumen that the array that makes claim 26 or the method by claim 13 obtain or the multiple protein or the peptide of peptide or claim 20 contact with the sample of at least a immunizing composition that contains the experimenter

Wherein said experimenter once was exposed to described infectious agent,

The interaction of the albumen of wherein said protein arrays or peptide and immunizing composition has identified that described albumen or peptide have immunocompetence.

30. the method for claim 29, wherein said infectious agent are the attenuation forms.

31. the method for claim 29, wherein said immunocompetence are the humoral immunization activity, sample comprises described experimenter's serum or blood plasma, and described interaction is the interaction with antibody.

32. the method for claim 31, wherein said serum or blood plasma are used with the antibody mediated immunity reacted composition and anticipated, described antibody does not react with infectious agent.

33. the method for claim 29, this method further comprise the peptide identified or albumen are contacted with the sample that comprises from the T cell of at least one type of described experimenter.

34. the method for claim 29, wherein said immunocompetence are the cellular immunization activity, and sample comprises the T cell from least one type of described experimenter.

35. the method for claim 34, wherein said immunocompetence are to detect by at least a cytokine of expressing among the APC and/or described proteic formation.

36. the array of claim 26, it prepares by the following method:

(a) method that may further comprise the steps: express nucleotide sequence from expression system, described expression system is to extract described expression system by the mixture from cell transformed to obtain;

Described mixture is to obtain by gather in the crops described cell from culture under the condition of not separating single clone; Described culture is by obtaining with the expression system of described nucleotide sequence or the composition transformed host cell of described expression system; Or

(b) method that may further comprise the steps: express nucleotide sequence from expression system, described expression system is to obtain by the method that may further comprise the steps: with the nucleic acid and the linearizing plasmid transformed host cell that comprise described nucleotide sequence, the amount of wherein said nucleic acid and linearizing plasmid is each 1,000,000 cell 1-10ng nucleic acid.

37. immunogenic composition, said composition comprises and is selected from three kinds or more kinds of immunoreactive protein or peptide that is selected from down group: ATI locus albumen, A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L, H5R, A26L, A27L, E3L, L4R, H7R, A17L, A3L, A4L, D11L, H6R, K2L, N1L, A41L, A47L, B2R, D10R, E1L, F2L, F9L, G5R, G7L, H7R, I1L, L5R and O2L, and basic homologous albumen and immunocompetence fragment.

38. the immunogenic composition of claim 37, wherein said immunoreactive protein or peptide are selected from ATI locus albumen, A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L, H5R, A26L, A27L, E3L, L4R, H7R, A17L, A3L, A4L, D11L, H6R, K2L, N1L, A41L, A47L, B2R, D10R, E1L, F2L, F9L, G5R, G7L, H7R, I1L, L5R and O2L, and basic homologous albumen and immunocompetence fragment.

39. the immunogenic composition of claim 38, wherein said immunoreactive protein or peptide are selected from ATI locus albumen, A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L, H5R, A26L, A27L, E3L, L4R, H7R, A17L, A3L, A4L, D11L, H6R, K2L and N1L, and basic homologous albumen and immunocompetence fragment.

40. the immunogenic composition of claim 39, wherein said immunoreactive protein or peptide are selected from A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L, H5R, A26L, A27L, E3L and L4R, and basic homologous albumen and immunocompetence fragment.

41. the immunogenic composition of claim 39, wherein said immunoreactive protein or peptide are selected from ATI locus albumen, A10L, A11R, A13L, A33R, A56R, B5R, D8L, D13L, F13L, H3L and H5R, and basic homologous albumen and immunocompetence fragment.

42. immunogenic composition, comprise at least a ATI of being selected from locus albumen, A10L, A13L, H3L, D13L, A11R and A17R and basic homologous albumen and the segmental immunoreactivity vaccinia virus of immunocompetence albumen, described albumen is optional to be mixed with one or more extra immunoreactivity vaccinia virus albumen.

43. immunogenic composition, comprise at least a ATI of being selected from locus albumen, A10L, A13L, A26L, A56R, D8L, D13L, F13L, H5R and H3L and basic homologous albumen and the segmental immunoreactivity vaccinia virus of immunocompetence albumen, described albumen is optional to be mixed with one or more extra immunoreactivity vaccinia virus albumen.

44. the immunogenic composition of claim 43, wherein said vaccinia virus albumen is selected from TI locus albumen, A10L, D13L and H3L, and basic homologous albumen and the segmental immunoreactivity vaccinia virus of immunocompetence albumen.

45. immunogenic composition, comprise vaccinia virus H3L and be selected from down the immunoreactive protein or the peptide of group: vaccinia virus albumin A 10L, D13L, A11R, A13R, A33R, A56R, D13L, H5R, D8R, F13L, H5R, A17R, ATI locus albumen and A26L, and basic homologous albumen and immunocompetence fragment with two or more.

46. an immunogenic composition comprises vaccinia virus albumin A TI locus albumen or its basic homologous albumen and immunocompetence fragment.

47. an immunogenic composition comprises vaccinia virus albumin A 10L, D13L and H3L, or its basic homologous albumen and immunocompetence fragment.

48. an immunogenic composition comprises immunoreactive protein or peptide that two or more are selected from down group: vaccinia virus albumin A 10L, D13L, H3L, A11R, A13L, H5R, A17R, and basic homologous albumen and immunocompetence fragment.

49. immunogenic composition, comprise immunoreactive protein or peptide that one or more are selected from down group: the malaria albumen relevant, and basic homologous albumen and immunocompetence fragment with locus PFB0300c, PFE1590w, PFB0915w, PFB0310c, PFD0310w, PF7_0128, PF11_0509, PF10_0356 and PF10_0343.

50. immunogenic composition, comprise immunoreactive protein or peptide that one or more are selected from down group: the soil by FTT1269, FTT1747, FTT1696, FTT0975, FTT0901, FTT1477, FTT0472 and FTT0264 coding draws hot Frances Salmonella albumen, Frances Salmonella protein D naK, TM albumen, HSP60 and 17kd albumen, and basic homologous albumen and immunocompetence fragment.

51. composition, comprise immunoreactive protein or peptide that one or more are selected from down group: vaccinia virus albumin A 10L, D13L, H3L, A11R, A13R, A33R, A56R, D13L, H5R, D8R, F13L, H5R, A17R, ATI locus albumen, A26L, and basic homologous albumen and immunocompetence fragment.

52. an immunogenic composition comprises three kinds or more kinds of immunoreactive protein or peptide that is selected from down group: by tuberculosis Rv0440, Rv0467, Rv0475, Rv0538, Rv0674, Rv0685, Rv0798c, Rv0916c, Rv0934, Rv1801, Rv1860, Rv1926c, Rv1980c, Rv1984c, Rv2007c, Rv2031c, Rv2190c, Rv2220, Rv2376c, Rv2389c, Rv2446c, Rv2744c, Rv2873, Rv2875, Rv2875, Rv3270, Rv3330, Rv3333c, Rv3418c, Rv3763, Rv3803c, Rv3828c, Rv3846, Rv3874, Rv3875 and Rv3881c encoded protein or peptide.

53. the composition of claim 52, wherein said peptide or albumen are selected from the peptide by mycobacterium tuberculosis gene Rv0440, Rv1801, Rv2031c, Rv2376c, Rv2875 and Rv3875 coding.

54. the composition of claim 52, wherein said peptide or albumen are selected from the peptide by mycobacterium tuberculosis gene Rv0440, Rv0475, Rv1801, Rv1980c, Rv2220, Rv2873, Rv2875, Rv3270, Rv3763 and Rv3875 coding.

55. an immunogenic composition comprises three kinds or more kinds of immunoreactive protein or peptide that is selected from down group: by plasmodium falciparum gene PFB0915w, PFB0310c, PFB0300c, PFB0305c, PFL2410w, PFC0210C, PFD0310w, PFD0310w, PF13_0197, PF100138, PFI1520w, PFI1520w, PF11_0344, PF13_0012, PFD0310w, PF11_0358, PF07_0029, PFL1605w, PFE1590w, MAL6P1.201, PFD0235c, PF13_0201, PF13_0267, PF07_0128, PF10_0343, PF10_0343, PFI1520w, PFI0580c, PF07_0020, PFE0520c, MAL7P1.29 and PF10_0260 encoded protein or peptide.

56. the immunogenic composition of claim 55 comprises three kinds or more kinds of albumen or peptide that is selected from down group: by plasmodium falciparum gene PFB0915w, PFB0310c, PFB0300c, PFB0305c, PFL2410w, PFC0210c, PFD0310w, PFD0310w, PF13_0197, PF10_0138, PFI1520w, PFI1520w, PF11_0344, PF13_0012, PFD0310w, PF11_0358, PF07_0029, PFL1605w, PFE1590w and MAL6P 1.201 encoded protein or peptide.

57. an immunogenic composition comprises one or more isolated nucleic acid molecule, described nucleic acid molecule comprises one or more any one albumen of coding claim 37-56 or the nucleotide sequence of peptide.

58. protection experimenter method of combating infection, this method comprises any one composition of the claim 37-56 that gives described experimenter's significant quantity.

59. protection experimenter method of combating infection, this method comprises the composition of the claim 57 that gives described experimenter's significant quantity.

60. specificity is incorporated into any one albumen of at least a claim 37-56 or the monoclonal antibody of peptide.

61. comprise the immunogenic composition of the monoclonal antibody of claim 60.

62. the experimenter is carried out the method for passive immunization, and this method comprises the immunogenic composition of the claim 61 that gives described experimenter's significant quantity.

63. detect experimenter's the immunizing composition and the interactional method of test substances, described test substances is included in first sample, described first sample contains extra material, and this experimenter is contained the immunizing composition at described extra material, and this method comprises

With second sample of described extra mass treatment available from described experimenter, thereby described second sample of first sample preparation is used in the interaction of blocking-up and described additional material then.

64. the method for claim 63, wherein said extra material comprises the composition of cell, and described test substances is to produce with the system that derives from described cell.

65. the method for claim 63, wherein said test substances are albumen or the peptides that derives from infectious agent, and described experimenter once was exposed to described infectious agent.

66. identify the infectious agent among the experimenter or the method for morbid state, comprise that distinctive at least two kinds with infectious agent or morbid state have immunocompetent albumen or peptide determines whether the experimenter has the antibody of this characteristic albumen or peptide.

67. the method for claim 66, wherein distinctive to have immunocompetent albumen or peptide be to identify by the method for claim 29.

Images